



The physiological roles of tau and A β : implications for Alzheimer's disease pathology and therapeutics

Sarah A. Kent¹ · Tara L. Spires-Jones² · Claire S. Durrant²

Received: 30 June 2020 / Revised: 20 July 2020 / Accepted: 20 July 2020 / Published online: 29 July 2020
© The Author(s) 2020

Abstract

Tau and amyloid beta (A β) are the prime suspects for driving pathology in Alzheimer's disease (AD) and, as such, have become the focus of therapeutic development. Recent research, however, shows that these proteins have been highly conserved throughout evolution and may have crucial, physiological roles. Such functions may be lost during AD progression or be unintentionally disrupted by tau- or A β -targeting therapies. Tau has been revealed to be more than a simple stabiliser of microtubules, reported to play a role in a range of biological processes including myelination, glucose metabolism, axonal transport, microtubule dynamics, iron homeostasis, neurogenesis, motor function, learning and memory, neuronal excitability, and DNA protection. A β is similarly multifunctional, and is proposed to regulate learning and memory, angiogenesis, neurogenesis, repair leaks in the blood–brain barrier, promote recovery from injury, and act as an antimicrobial peptide and tumour suppressor. This review will discuss potential physiological roles of tau and A β , highlighting how changes to these functions may contribute to pathology, as well as the implications for therapeutic development. We propose that a balanced consideration of both the physiological and pathological roles of tau and A β will be essential for the design of safe and effective therapeutics.

Keywords Synapse · Myelination · Vasculature · Memory · Therapeutics · Microtubule dynamics

Abbreviations

A β	Amyloid beta	BACE1	Beta-site amyloid precursor protein cleaving enzyme 1
AD	Alzheimer's disease	BBB	Blood–brain barrier
AICD	A β intracellular domain	BDNF	Brain-derived neurotrophic factor
AMP	Antimicrobial peptide	CAA	Cerebral amyloid angiopathy
APP	Amyloid precursor protein	CBD	Corticobasal degeneration
ARIA	Amyloid-related imaging abnormalities	CCI	Controlled cortical impact
ASD	Autism spectrum disorder	CNS	Central nervous system
		CSF	Cerebrospinal fluid
		EAE	Experimental autoimmune encephalomyelitis
		FTD	Frontotemporal dementia
		FTD-P17	Frontotemporal dementia with parkinsonism 17
		HSV	Herpes simplex virus
		iPSC	Induced pluripotent stem cell
		LTD	Long-term depression
		LTP	Long-term potentiation
		MAP	Microtubule-associated protein
		MAPT	Microtubule-associated protein tau
		MBP	Myelin basic protein
		MS	Multiple sclerosis
		MWM	Morris Water Maze
		NFTs	Neurofibrillary tangles

✉ Claire S. Durrant
claire.durrant@ed.ac.uk

Sarah A. Kent
sarah.kent@ed.ac.uk

Tara L. Spires-Jones
tara.spire-jones@ed.ac.uk

¹ Translational Neuroscience PhD Programme, Centre for Discovery Brain Sciences and the UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, Scotland, UK

² Centre for Discovery Brain Sciences and the UK Dementia Research Institute, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, Scotland, UK

PD	Parkinson's disease
PNS	Peripheral nervous system
PSD	Postsynaptic density
PS1	Presenilin-1
PSP	Progressive supranuclear palsy
rDNA	Ribosomal DNA
ROS	Reactive oxygen species
SCI	Spinal cord injury
TBI	Traumatic brain injury
TGN	Trans-Golgi network
TTLL6	Tubulin tyrosine ligase-like 6
3R	Tau with 3 microtubule-binding domains
4R	Tau with 4 microtubule-binding domains

Introduction

Alzheimer's disease (AD) is a terminal neurodegenerative disorder associated with severe progressive dementia [155]. The disease is characterised by key neuropathological hallmarks of chronic inflammation, synapse loss, neuronal death and the diagnostic accumulation of insoluble protein aggregates, intracellular neurofibrillary tangles (NFTs), and extracellular amyloid plaques [28, 155, 258]. The disease begins as a primary disorder of short-term memory, learning, and spatial navigation, due to early degeneration of the temporal lobe [174]. In the end stages, however, the spread of pathology throughout the brain results in multimodal deficits, including loss of verbal and motor control [174]. Unfortunately, AD is a common disorder, affecting over 50 million individuals worldwide and representing 60–80% of all dementia cases [5]. Whilst there is evidence that dementia incidence may be declining in the population, potentially attributable to better management of modifiable risk factors, it is not yet known whether this trend will counteract the impact of a shift towards an ageing population [57, 229]. As the population ages, and the risk of developing dementia increases, AD cases are currently set to triple by the year 2050, representing a tremendous global, socio-economic challenge [5]. As existing treatments only target symptoms and do not slow (let alone halt or reverse) the progression of the disease, the need to develop a disease-modifying therapeutic has never been more urgent [155].

Since the identification of microtubule-associated protein tau (MAPT) and amyloid beta (A β) as the components of NFTs and extracellular plaques, respectively, research has primarily focused on the toxic roles these proteins play in AD pathogenesis [136, 171, 241]. Accumulation of A β causes synapse damage [106, 132, 274] and can induce cognitive and electrophysiological deficits [270]. Similarly, whilst tau was discovered as a microtubule-associated protein (MAP) [276], attention has been drawn to the toxic effects of tau hyperphosphorylation and aggregation [9]. As

such, therapeutic development has focused heavily on targeting these proteins through preventing their aggregation, inhibiting their production, or promoting their clearance [155]. Despite promising results in pre-clinical studies, no clinical trials have produced meaningful benefits for patients, with trials being halted due to adverse side effects such as liver toxicity, encephalitis, vasogenic oedema, and even exacerbation of cognitive decline [203, 286]. It is becoming increasingly apparent that the involvement of “pathological” proteins in AD is complex and nuanced [241]. There is mounting evidence that these proteins may serve a number of crucial physiological functions that could be disrupted in the development of AD pathology or by A β - or tau-lowering therapeutics.

In this review, we discuss the emerging evidence for key physiological roles of tau and A β . The toxic roles of these proteins have been extensively reviewed elsewhere [94, 155, 241], and thus, we aim to highlight possible loss of function phenotypes in disease, as well as identify potentially detrimental side effects of tau- (Table 1) or A β (Table 2)-lowering therapeutics if not appropriately targeted. This will be especially important when considering treatment of the adult nervous system, where the lack of developmental compensation may reveal phenotypes masked in constitutive knock-outs. We propose that balancing the consideration of both physiological and pathological roles of tau and A β will be essential for the design of safe and effective AD therapeutics.

The origin of A β and tau

A β biogenesis

Amyloid precursor protein (APP) is encoded by the *APP* gene on chromosome 21 [84, 125, 257]. A β is produced by the sequential cleavage of APP by beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) [265] and γ -secretase [55], which have recently been shown to form a multiprotease complex to maximise cleavage efficiency [151] (Fig. 1a). BACE1 cleaves APP at Asp1 or Glu11 of the A β sequence [265], after which the catalytic component of γ -secretase (presenilin) sequentially trims the resulting carboxy-terminal fragment at ϵ -, ζ -, and γ -cleavage sites, releasing the A β intracellular domain (AICD) and A β (between 37 and 49 amino acids in length) [292]. Mutations in presenilin, or environmental factors, consistently decrease the processivity of γ -secretase, resulting in fewer cuts per APP molecule and consequentially the release of longer A β peptides [42]. This amyloidogenic (or β) cleavage of APP is in direct competition with an alternative α -cleavage pathway, where α -secretase bisects APP in the middle of the putative A β protein, thus preventing A β production [70]. Under physiological conditions, A β ₁₋₄₀ (~90% of total A β) and A β ₁₋₄₂

Table 1 Adverse effects of lowering tau

Role	Experimental paradigm	Adverse effects	References
Microtubules			
Regulation of microtubule dynamics	Tau knockdown	↓ In labile microtubule mass, ↑ in the stable domain	Qiang et al. [213]
	Tau knockdown	↓ Neuronal outgrowth	Liu et al. [150]
	Tau knockdown	Impaired repulsive response of the growth cone	Biswas and Kalil, [22], Li et al. [147]
	Tau knockdown	Disruption to axonal extension	Caceres and Kosik [36]
	Tau knockdown/ knockout	Delayed neuronal maturation	Caceres et al. [37], Dawson et al. [54]
	Tau knockout	↓ Microtubule density in small caliber axons	Harada et al. [96]
	No tau added to microtubules in vitro (compared to tau presence)	↑ EB1 binding to microtubule ends, ↑ catastrophe frequency	Ramirez-Rios et al. [217]
Regulation of axonal transport	4R tau knockdown	↑ Velocity of mitochondrial axonal transport	Beevers et al. [15]
Protection of microtubules from cleavage	Tau knockdown	Katanin-mediated cleavage, loss of microtubules and ↓ axon length	Qiang et al. [214]
	Tau knockdown	↑ Neuronal branching	Yu et al. [287]
Synaptic Activity			
LTP, LTD and memory	Tau knockout	Age-dependent cognitive deficits in contextual fear conditioning, Y-maze, Morris Water Maze and reversal learning tests	Ahmed et al. [3], Lei et al. [146], Ma et al. [164], Regan et al. [218]
	Tau knockout	Severe LTP deficit	Ahmed et al. [3]
	Tau knockout	LTD deficits	Kimura et al. [128], Regan et al. [218]
	Acute tau knockdown using shRNA	↓ Dendritic spine density, loss of synaptic proteins and significant spatial memory impairments (no compensatory MAP upregulation)	Velazquez et al. [266]
Regulation of neuronal hyperexcitability	Tau knockout	Hyperpolarised neuronal membrane potential	Pallas-Bazarra et al. [197]
	Tau knockout	Impaired basal neurotransmission when crossed with APP transgenic mouse	Puzzo et al. [209]
Neurogenesis and synaptogenesis	Acute tau knockdown using shRNA	↓ In baseline spine numbers, pro-synaptic response to BDNF blocked	Chen et al. [44]
	Acute tau knockdown using shRNA	↓ Apical and basal dendrite density	Velazquez et al. [266]
	Tau knockout	Failed normal migration of new-born granule neurons in the dentate gyrus	Fuster-Matanzo et al. [78], Sapir et al. [227]
	Tau knockout	↓ Dendritic length, disrupted PSD and mossy fiber terminal formation	Pallas-Bazarra et al. [197]
	Tau knockout	Impaired neurogenesis	Hong et al. [107]
	Tau knockout	Delayed neuronal maturation	Dawson et al. [54]
	Tau knockout	Transcriptional repression of neuronal genes	de Barreda et al. [11]
	Tau knockout	Hyperactivity	Biundo et al. [23], Ikegami et al. [114]
Behaviour			
Hyperactivity	Tau knockout	↑ Rearing behaviour	Lei et al. [146]
Anxiety	Tau knockout	↑ Anxiety in open field arenas	Gonçalves et al. [86]
Sleep	Tau knockout	↑ Wakefulness and disruption to normal circadian activities	Arnes et al. [8], Cantero et al. [41]

Table 1 (continued)

Role	Experimental paradigm	Adverse effects	References
Motor function			
	Tau knockout	FTD-P17-like motor dysfunction	Lei et al. [145]
	Tau knockout	Changes in gait, ↓ locomotion and muscle weakness	Lei et al. [145, 146], Ikegami et al. [114]
	Tau knockout	Loss of dopaminergic neurons	Lei et al. [145], Ma et al. [164]
	Tau knockout, tau 4R knockout, acute tau knockdown using shRNA	Significant impairment in balance beam or rotarod performance	Lei et al. [145, 146], Morris et al. [186], Lopes et al. [157], Ikegami et al. [114], Ma et al. [164], Gumucio et al. [93], Velazquez et al. [266]
Myelination			
Regulation of myelination	Tau knockdown using siRNA	↓ Oligodendrocyte process outgrowth, ↓ myelin basic protein expression, ↓ contact with axons	Seiberlich et al. [230]
	Tau knockdown using siRNA	↓ Recovery after sciatic nerve damage, defective myelin debris clearance, impaired Schwann cell migration and differentiation	Yi et al. [285]
	Tau knockout	Age-dependent degeneration of myelinated fibers, ↓ nerve conduction and progressive hypomyelination, resulting in motor and nociceptive impairments	Lopes et al. [157], Sotiropoulos et al. [237]
	Tau knockout	Worse clinical outcome after experimental autoimmune encephalomyelitis (EAE)	Weinger et al. [277]
	Expression of an inducible, truncated tau	Demyelination and development of gait abnormalities	LoPresti [160]
Response to injury			
Promotion of recovery	Tau knockout	↓ Recovery after sciatic nerve damage	Yi et al. [285][1]
	Tau knockout	Worse outcome after EAE	Weinger et al. [277]
	Tau knockdown	↓ Mitochondrial mobility and ↑ number of abnormal mitochondria	Sapir et al. [227]
Mitochondrial activity			
Mitochondrial mobility and health	Tau knockout	Age-dependent iron accumulation associated with neurodegeneration, cognitive deficits and parkinsonian-like motor deficits, deficits rescued by treatment with the iron chelator clioquinol	Lei et al. [144, 145]
Iron			
Regulation of iron homeostasis	Lithium-mediated tau reduction	↑ Iron accumulation in the brain, ↓ cellular efflux of iron	Lei et al. [143]
	Tau knockout	Extensive heat shock damage (DNA breaks) in neurons	Sultan et al. [246]
Nuclear activity			
Protection of DNA from damage	Tau knockout	↑ DNA fragmentation under physiological conditions and high susceptibility to DNA breakage after hyperthermic stress	Violet et al. [267]
	Tau knockout	Delayed repair of double-strand breaks after heat shock	Violet et al. [267]
Maintenance of chromosomal stability	Knockout of one or both copies of tau	Marked ↑ in aneuploidy	Granic et al. [88], Rossi et al. [222]
Regulation of transcription	Tau knockout	Disrupted pericentromeric heterochromatin	Maina et al. [165], Mansuroglu et al. [169]
	Tau knockdown using shRNA	↓ mRNA and protein levels of VGLUT1	Siano et al. [234]

Table 1 (continued)

Role	Experimental paradigm	Adverse effects	References
Tumour suppression	Tau knockout	Upregulation of proteins such as BAF-57 (involved in neuron-specific gene repression)	de Barreda et al. [11]
	Tau knockdown	rDNA transcription altered	Maina et al. [165], Samra et al. [226]
	Tau knockdown	Enhanced cell growth and invasion in clear cell renal cell carcinoma	Han et al. [95]
Glucose metabolism	Tau knockout	Insulin resistance in the hippocampus	Marciniak et al. [170]
	Tau knockout	Pancreatic β cell dysfunction and glucose intolerance	Wijesekara et al. [279]

Summary of studies reporting adverse outcomes after lowering tau in a range of experimental systems

(~5–10% of total A β) are the most abundant isoforms in humans [184]. A β_{1-40} is produced exclusively within the trans-Golgi network (TGN) and then packaged into secretory vesicles, whilst A β_{1-42} can be made in either the TGN or the endoplasmic reticulum [91]. A β monomers readily assemble to form higher order structures, from low-molecular-weight oligomers, to protofibrils and eventually to fibrils containing β -sheets (Fig. 1b), with longer isoforms of A β showing the greatest propensity to oligomerise and aggregate [34]. Increased production of A β_{1-42} , at the expense of A β_{1-40} generation, is a common feature of both familial [42] and sporadic AD [101], with the increased aggregation of this peptide believed to be responsible for driving neurotoxicity [34].

Tau production

Tau is encoded by the *MAPT* (microtubule-associated protein tau) gene on chromosome 17 [189], which generates a total of 6 tau protein isoforms through alternative splicing of exons 2, 3, and 10 in the central nervous system (CNS) [94] (Fig. 2a). Inclusion of exon 10 produces tau with 4 microtubule-binding domains (4R), whilst omission of exon 10 excludes microtubule-binding domain R2 (3R). Similarly, tau can include (2 N or 1 N) or exclude (0 N) amino-terminal inserts through regulation of exons 2 and 3. In the peripheral nervous system (PNS), exons 4A, 6, and 8 can also be transcribed, resulting in the production of larger tau proteins [75]. Tau expression is developmentally regulated, with only 0N3R tau being expressed in the foetal brain, whilst all isoforms are expressed in adult humans [94]. However, adult mice and rats show almost exclusive expression of 4R tau [94]. In humans, there are two principle genetic haplotypes at the *MAPT* locus; H1, which is directly orientated (~75% of the Caucasian population), and H2, which has an inverted sequence (~25% of the Caucasian population) [269]. Interestingly, the H2 haplotype appears to be almost exclusively Caucasian in origin, with Central Asian populations having H2 allele frequencies of ~5% and African, East Asian, and Native American populations effectively lacking H2 expression [71]. Possession of the H1 versus H2 haplotype subtly alters the tau isoform expression profile [269]. Tau can undergo a vast array of post-translational modifications including phosphorylation, acetylation, ubiquitination, sumoylation, methylation, glycation, glycosylation, polyamination, nitration, isomerisation, and oxidation (reviewed in [94]). Tau monomers can aggregate to form oligomers and higher order fibrils (Fig. 2b). However, whilst A β can largely self-assemble, tau phosphorylation is believed to be important for its aggregation [9].

Table 2 Adverse effects of lowering A β

Role	Experimental paradigm	Adverse effects	References
Synaptic activity <i>LTP</i>	<i>APP</i> or <i>BACE1</i> knockout	Cognitive deficits induced and impaired LTP	Dawson et al. [53], Laird et al. [139], Lombardo et al. [154], Wang et al. [272, 273]
	Treatment with anti-A β antibody 4G8	LTP formation prevented	Morley et al. [185], Puzzo et al. [210]
	Infusion of anti-A β antibody 4G8 or siRNA to APP	Short-term memory abolished in contextual fear conditioning or the Morris Water Maze	Garcia-Osta and Alberini [81], Morley et al. [185], Puzzo et al. [210]
	<i>BACE1</i> inhibitor treatment (wild-type mice)	Suppression of LTP, impaired cognitive performance	Filser et al. [74]
Regulation of neuronal hyperexcitability	<i>APP</i> or <i>BACE1</i> knockout	Hypersensitivity to spontaneous and induced seizures	Hitt et al. [103], Hu et al. [112], Kobayashi et al. [130], Steinbach et al. [243]
Neurogenesis and synaptogenesis	<i>APP</i> knockout	Neuronal branching and synapse formation	Southam et al. [239]
	<i>APP</i> knockout	Loss of synaptic proteins	Dawson et al. [53], Seabrook et al. [228]
	<i>BACE1</i> knockout	Hearing impairment linked to aberrant synaptic organisation in the cochlea	Dierich et al. [60]
Myelination Regulation of myelination	<i>BACE1</i> inhibitor treatment (wild-type mice)	Spine density, \downarrow spine formation	Filser et al. [74]
	<i>BACE1</i> knockout	Delayed myelination, \downarrow myelin thickness	Hu et al. [110], Willem et al. [280]
	<i>BACE1</i> knockout	Impaired remyelination of peripheral nerves after injury	Hu et al. [109, 111]
	<i>BACE1</i> knockout	\downarrow In retinal vascular density	Cai et al. [38]
Role in blood vessels Promotion of angiogenesis	APP-deficiency or <i>BACE1</i> inhibitor treatment	Shorter hindbrain vessels, fewer cerebrovascular branches	Luna et al. [163]
	γ -secretase inhibitor treatment	\uparrow Angiogenesis and vascularisation	Cameron et al. [40]
	A β -targeting drugs (active or passive A β immunisation) in human clinical trials	Microhaemorrhages and brain oedema (“Amyloid-Related Imaging Abnormalities” (ARIA))	Penninkilampi et al. [203], Sperling et al. [240]
	A β immunisation (animal models)	ARIA-like cerebral microbleeds	Blockx et al. [24], Joseph-Mathurin et al. [121]
	<i>APP</i> or <i>BACE1</i> knockout	\uparrow Mortality after ischaemic injury, deficits in reactive blood flow	Koike et al. [133]
Response to injury Promotion of recovery	<i>BACE1</i> knockout	Impaired remyelination after sciatic nerve lesion	Hu et al. [109, 111]
	<i>BACE1</i> knockout	Worse functional outcome after spinal cord injury	Pajooohesh-Ganjji et al. [195]
	<i>BACE1</i> knockout	Worse outcome after controlled cortical impact (rescued by A β application)	Mannix et al. [167, 168]
Antimicrobial activity	<i>BACE1</i> or <i>APP</i> knockout	\uparrow Risk of mortality following cerebral ischaemia	Koike et al. [133]
	<i>APP</i> knockout	\uparrow Mortality after infection	Kumar et al. [138]
	A β -targeting therapies	\uparrow Incidence of infections	Gosztyla et al. [87]
	<i>APP</i> knockout	\uparrow Neuronal iron retention in vitro, \uparrow vulnerability to oxidative damage from dietary iron in vivo	Duce et al. [63]

Table 2 (continued)

Role	Experimental paradigm	Adverse effects	References
	APP knockout	Age-dependent iron accumulation in the brain and liver	Belaïdi et al. [16]
Glucose metabolism	BACE1 knockout	↓ Insulin expression in the pancreas	Hoffmeister et al. [104]
	BACE1 knockdown (siRNA)	↓ Insulin mRNA and protein in insulinoma cells	Hoffmeister et al. [104]

Summary of studies reporting adverse outcomes after lowering A β in a range of experimental systems




Fig. 1 **a** The two pathways through which APP can be cleaved. The non-amyloidogenic (α) pathway (left-hand side of diagram) involves the cleavage of APP by α -secretase, within the A β sequence, to form C-terminal fragment α (CTF α) and soluble APP α (sAPP α). γ -secretase then cleaves the resulting CTF α , releasing the A β intracellular domain (AICD) and the extracellular p3 fragment. The amyloidogenic (β) pathway (right-hand side of the diagram) involves the cleavage of APP by BACE1 to form CTF β and sAPP β . γ -secretase then cleaves the resulting CTF β , releasing the AICD and A β . **b** A β monomers can assemble to form higher order structures, from oligomers, to protofibrils and eventually mature fibrils containing β -sheets which form the core component of amyloid plaques. Created with <https://biorender.com/>

A β and tau are expressed throughout the body

Tau and the key proteins required to produce A β [APP, BACE1, and components of γ -secretase (presenilin-1)] are expressed in a variety of tissues throughout the body (as reported by The Human Protein Atlas [262] (Fig. 3)). Whilst tau is predominantly found in brain and peripheral nerves, tau protein expression has been detected in diverse locations including salivary glands, breast tissue, cardiac myocytes, skeletal muscle, the pancreas, and kidneys [296]. Similarly, in addition to the brain, the key components of the A β -processing pathway [APP, BACE1, and presenilin-1 (PS1)] are co-expressed in the pancreas, appendix, gastrointestinal tract, and both male and female reproductive organs [297–299]. It is likely, therefore, that both A β and tau will serve functions beyond the CNS.

A β and tau are evolutionarily conserved

Both tau and A β show remarkable evolutionary conservation. An A β -like sequence has been reported in sea




Fig. 2 **a** Tau is encoded by the *MAPT* gene on chromosome 17. A total of 6 tau protein isoforms are generated via alternative splicing of exons 2, 3, and 10. Inclusion of exon 10 produces tau with 4 microtubule-binding (MTB) domains (4R), with omission of exon 10 producing tau with 3 MTB domains (3R). Tau can include (2 N or 1 N) or exclude (0 N) amino-terminal inserts through regulation of exons 2 and 3. Only 0N3R tau is expressed in the foetal human or mouse brain, with all 6 tau isoforms being expressed in adult humans. Adult mice and rats show almost exclusive expression of 4R tau. **b** Phosphorylated tau monomers can assemble to form oligomers, filaments (both straight and paired helical) and eventually tangles. *N* N-terminus, *PRD* proline-rich domain, *MTB* microtubule-binding domains, *C* C-terminus. Created with <https://biorender.com/>

anemones, demonstrating that such peptides have been in existence from 540 to 630 million years ago [259]. The human A β sequence is over 95% homologous to that in other mammals, and over 90% in birds, reptiles, and amphibians [259]. Similarly, evidence of a *MAPT*-like gene has been found in lampreys, hagfish, and sharks, pinpointing an origin over 550 million years ago [247]. Such evolutionary conservation raises the possibility that these proteins are involved in key biological functions. Identifying these functions will provide a greater understanding of the pathogenesis of AD, as well as informing how A β - or tau-targeting treatments could impact physiology.

Regulation of microtubules: the primary physiological role of tau?

Tau binds to and regulates the structure of microtubules

Since the discovery of tau in 1975 [276], a plethora of research has focused on the role of tau at microtubules

(reviewed in [10]). Microtubule deficits are common in AD and related disorders, with studies reporting axonal transport deficits [1], and defective microtubule assembly [115]. Tau binds tubulin via its microtubule-binding domains [141], with a single tau molecule crosslinking multiple tubulin dimers [6]. Original studies found that tau stabilises microtubules [62], reducing the frequency of catastrophes (sudden microtubule disintegration) [208]. Early studies found that tau reduces the concentration of tubulin required for polymerisation [276]. A mechanism for this process has recently been proposed, where conditions of macro-molecular crowding induce tau to form liquid-like drops [102]. Tubulin partitions into these drops, effectively raising its concentration to drive nucleation of microtubule formation [102]. Crucially, tau from AD post-mortem brain tissue fails to stimulate microtubule formation [115] and hyperphosphorylation of tau [115, 192], mutations within microtubule-binding sites [83], or C-terminal truncation [192], all greatly reduce tau's microtubule-binding capacity. These findings have contributed to the established dogma that disease-associated hyperphosphorylation of tau promotes its dissociation from microtubules, reducing microtubule stability [9]. Whilst pseudo-phosphorylation of tau results in a fivefold decrease in the association rate of binding to microtubules, this surprisingly does not impact tau's *dissociation* rate, raising the question of whether tau hyperphosphorylation occurs prior to, or following, microtubule detachment in disease [192]. In support of the latter hypothesis, inducing microtubule catastrophe via stathmin application results in unphosphorylated tau falling off the microtubule and subsequently being phosphorylated in the cytoplasm [181]. Thus, the role of microtubule-associated tau appears to be more complex than originally thought, with recent studies demonstrating its diverse, subtle, and sometimes contradictory functions.

Beyond microtubule stability: tau as a regulator of microtubule dynamics

Tau is preferentially expressed within the axon and there is agreement that tau concentration increases towards the distal, labile end [213]. As such, a role for regulating microtubule *dynamics* has been proposed. Indeed, tau knockdown in primary neurons results in a substantial drop in the labile microtubule mass with a corresponding increase in the stable domain [213]. Tau knockdown reduces neuronal outgrowth [150], impairs the repulsive response of the growth cone [22, 147], disrupts axonal extension [36], delays neuronal maturation [37, 54], and reduces microtubule density [96]. Tau also recruits end-binding proteins (EBs) to the stable microtubule bundle, preventing them from tracking to microtubule ends where they increase catastrophe frequency [217]. However, not all tau depletion studies report deficits in microtubule dynamics [261], with compensatory increases in other




Fig. 3 Tissue-level protein expression of APP [297], BACE1 [298], and presenilin-1 [299] (indicating potential for A β production) and tau (MAPT) [296] according to the Human Protein Atlas [262]. Created with <https://biorender.com/>

MAPs potentially masking relevant functions [164, 266]. Indeed, *MAPT* and *MAP1B* double knockouts have a high mortality rate, showing a synergistic disruption to growth cone dynamics, axonal elongation, and neuronal migration, resulting in defective axonal tract and neuronal layer formation [252]. Interestingly, an individual with frontotemporal dementia (FTD) was found to have a partial deletion of the *MAPT* gene, resulting in the production of truncated tau lacking the first microtubule-binding repeat [224]. This truncated tau exhibited dramatic reduction in microtubule-binding capability, but acquired the ability to sequester MAP1B, potentially mediating both loss-of-function and gain-of-function disruption to microtubule dynamics, similar to double knockout mice [224].

Tau regulates axonal transport

Many studies have sought to determine whether tau regulates axonal transport. Knockdown of 4R tau in human induced pluripotent stem cell (iPSC)-derived neurons *increases* the velocity of mitochondrial transport [15]. Additionally, young P301L knockin mice, which exhibit reduced tau-microtubule binding, show enhanced anterograde transport [1, 83]. It is hypothesised that tau may compete with motor proteins for tubulin-binding sites, and overexpression of tau has been reported to cause “traffic jams” [242] and induce kinesin dissociation from microtubules [61, 65, 233, 255]. Tau fibrils

or oligomers can also inhibit axonal transport [124] and *MAPT*^{-/-} neurons are resistant to A β -induced axonal transport deficits [268]. Recent work has demonstrated a potential mechanism for this under physiological conditions, with two studies describing “island” regions of concentrated tau protein along the axon [233, 255]. Upon reaching the island boundaries, kinesin-1 motor proteins dissociate instantaneously from the microtubules, whilst dynein slowly moves through [233, 255]. Such differential regulation of motor proteins could allow tau to regulate axonal transport and cargo delivery, processes that may be disrupted in disease. However, other studies report that neither tau knockout nor overexpression alters axonal transport dynamics [288]. A “kiss-and-hop” binding of tau to tubulin has been proposed as a mechanism, whereby tau remains associated with microtubules without clogging motor protein binding sites [118].

Tau protects microtubules from cleavage

An emerging role of tau is protecting microtubules from the microtubule-severing protein katanin [214, 233, 255, 287]. Recently described “tau islands” block katanin-tubulin binding, preventing breakdown of the microtubule lattice at these sites [233, 255]. Indeed, tau knockdown [214], or expression of pseudo-hyperphosphorylated tau [245], results in katanin-mediated cleavage, loss of microtubules, and reduced axon length in vitro. Tau depletion also increases neuronal

branching [287], raising the hypothesis that the preferential expression of tau in the axon may maintain a non-branched structure, in contrast to highly branched dendrites, which show low tau expression [287]. Pathological tau mislocalisation may, therefore, render axonal microtubules vulnerable to inappropriate cleavage [233]. Interestingly, A β -induced tau mis-sorting permits recruitment of tubulin tyrosine ligase-like 6 (TTL6) to dendritic microtubules, promoting spastin-mediated cleavage [289]. Tau *location*, therefore, appears vital for regulating its physiological versus pathological functions. Indeed, dendritic mis-sorting of tau also promotes aberrant clustering of Fyn, a key step in A β -mediated synaptotoxicity and spine collapse [116].

The future of therapeutics targeting microtubule (dys)function

Whilst microtubule-stabilising drugs, such as Taxol and Etoposide, showed pre-clinical promise, replication of this success in humans is not yet forthcoming [286]. Forty five years of exploration of tau at the microtubule has transformed understanding from tau being a simple “stabiliser”, to reveal a diverse array of physiological and pathological functions [10]. With development of tau-targeting therapies becoming increasingly common, careful maintenance of physiological tau at the axon, whilst also preventing mis-sorting and pathological aggregation, will likely be crucial for therapeutic success. Interestingly, a recent study reported that A β -mediated dendritic simplification requires microtubule stabilisation by unphosphorylated dendritic tau [85]. This finding raises concerns that reducing tau phosphorylation, a common goal of tau-targeting treatments, may negatively impact neuronal connectivity in some circumstances, highlighting the complexity of untangling physiological from pathological modifications. Therefore, focus on other physiological functions of tau or A β may reveal more promising therapeutic targets.

Physiological roles at the synapse

Synapse loss is the strongest pathological correlate of cognitive decline in AD [56, 258], so protecting these vital structures is a key therapeutic goal. Tau and A β are prime suspects for causing synaptic damage, with toxic species reported to accumulate at synapses [132, 250], disrupt key synaptic machinery [293], induce spine collapse [274], and target synapses for microglia-mediated pruning [52, 106]. Whilst toxic tau and A β are undoubtedly involved in AD pathology, there is growing evidence that these proteins play key *physiological* roles at the synapse that could be lost, or hijacked, to contribute to disease. Potential loss-of-function at the synapse should be carefully considered when

designing tau- or A β -targeting therapeutics to avoid exacerbating, or introducing new, synaptic pathology.

Physiological concentrations of A β enhance LTP

Studies of synapse function often use long-term potentiation (LTP), an indicator of synapse strengthening, and long-term depression (LTD), an indicator of synaptic weakening, as electrophysiological correlates of learning and memory [14]. Pathological concentrations of A β applied to hippocampal slices disrupt LTP [270], but physiological concentrations may, in fact, be required for this process [210] (Fig. 4). A biphasic, or hormetic, role of soluble A β in regulating LTP has been proposed, whereby low (picomolar) concentrations of A β *enhance* LTP, whilst high (nanomolar) concentrations suppress LTP [92, 99, 185, 210, 211]. Such experiments highlight a potential role for endogenous A β in regulating memory formation. Indeed, the extracellular concentration of A β increases after neuronal stimulation [123, 253] and interstitial fluid A β concentration positively correlates with neuronal activity in human brain [29]. Interestingly, both *APP* knockout [53] and *BACE1* knockout [139, 154, 272, 273] *in vivo* induce cognitive deficits and impair LTP. Wild-type mice given *BACE1* inhibitors also show a dose-dependent suppression of LTP and impaired cognitive performance [74]. Treatment of wild-type slices with the anti-A β antibody




Fig. 4 Schematic representation of the hormetic responses to tau and A β concentration. There is an optimal concentration of tau or A β for a number of physiological functions. Too little protein (or loss of function modifications) or too much protein (or gain of function modifications) can both disrupt normal function. Effectively rescuing loss of function or preventing gain of function to maintain optimal physiological conditions should be the ultimate goal of therapeutics. Created with <https://biorender.com/>

4G8 prevents LTP formation [185, 210] with LTP restored by application of picomolar oligomeric A β_{1-42} [210]. In vivo, hippocampal infusion of 4G8 [81, 185, 210] or siRNA to APP [185, 210] abolishes short-term memory in contextual fear conditioning [81, 185, 210] or the Morris Water Maze (MWM) [210]. Infusion of picomolar A β rescues this effect [81, 210], whilst A β -infusion into naive mice *enhances* reference and contextual fear memory [81, 210, 211]. A potential hormetic role of A β raises the possibility that physiological, learning-mediated A β production throughout life could eventually result in accumulation of A β to a toxic level, especially if clearance mechanisms fail. Indeed, in humans, brain regions in the default mode network that show high levels of neuronal activity in young adults closely correlate with regions most heavily burdened by amyloid in AD later in life [32].

Tau in LTP, LTD, and memory

Like A β , tau expression and secretion also increases following neuronal activity [131, 207], and studies in *MAPT*^{-/-} mice have sought to explore the role of tau in synaptic function. Phenotypes of *MAPT*^{-/-} mice vary, with findings differing depending on the model used, genetic background [146], cleanliness of the animal unit [186], diet [164], and the age of the animals when studied. Some studies do not report cognitive or synaptic deficits in *MAPT*^{-/-} mice [113, 146, 186, 254], and reports that there is compensatory upregulation of other MAPs highlight that developmental compensation could mask relevant effects [164]. Ma et al. found that 8-month old *MAPT*^{-/-} mice had no cognitive deficits, but displayed significant MAP1A upregulation. At 19 months old, however, compensatory MAP levels fell, and extensive synapse loss and cognitive deficits became apparent [164]. A recent study showed that *acute* tau knockdown in adult mice using viral shRNA resulted in reduced spine density, loss of synaptic proteins, and significant spatial memory impairments in the absence of compensatory MAP upregulation [266]. Despite potential compensatory confounds, different groups have reported age-dependent cognitive deficits in *MAPT*^{-/-} mice in contextual fear conditioning [3], Y-maze [146], MWM [164], and reversal learning tests [218]. Whilst one study found a severe LTP deficit in tau knockouts [3], LTD deficits are more commonly reported [128, 218]. Tau's role in LTD appears to depend on its phosphorylation at serine 396 permitting AMPA receptor internalisation [218]. Crucially, a number of studies have reported human genetic cases of FTD [199, 294] or intellectual disability [172, 232, 263] in which tau levels are drastically *reduced* compared to age-matched controls. Reduced soluble tau has also been reported in

normal ageing [187], Parkinson's disease (PD) [145], and AD [137, 191] (potentially due to sequestration of tau into NFTs). Together, this raises the possibility that loss of normal tau function may be partly responsible for cognitive and synaptic deficits in disease. Tau-targeting therapeutics should, therefore, be carefully managed to avoid disrupting physiological tau at the synapse.

Regulating neuronal hyperexcitability: could tau and A β act at opposite ends of the spectrum?

A common feature of many neurodegenerative and neurodevelopmental disorders is the prevalence of seizures. Up to 22% of individuals with AD experience at least one seizure [178], whilst epilepsy is diagnosed in around 20% of individuals with autism spectrum disorder (ASD) [18]. Tau appears to be important for permitting seizure activity, and there is strong evidence that *MAPT*^{-/-} mice [148], or mice treated with tau antisense oligonucleotides [59] are resistant to pentylenetetrazol-induced seizures. Crossing *MAPT*^{-/-} mice with genetic models of epilepsy [105], AD [219] and ASD [249] can rescue hyperexcitability and spontaneous epileptiform activity. As such, a role for tau in promoting or regulating neuronal excitability seems likely. It has recently been shown that hyperexcitation increases tau translation [131] and that tau translocation to the nucleus regulates the expression of the glutamatergic transporter protein, VGLUT1 [234]. Interestingly, *MAPT*^{-/-} neurons lack extrasynaptic NMDA currents that, whilst their physiological role is under debate, mediate excitotoxicity under a number of conditions [196]. Tau deficiency may also impact basal synaptic activity; one study reported that tau knockout neurons were hyperpolarised compared to wild-type cells [197], and a recent study found that tau knockout impaired basal neurotransmission in APP transgenic mice [209]. Lowering of tau levels could, therefore, be beneficial under conditions of hyperexcitability, but this must be carefully balanced against the risk of depressing normal neuronal activity.

When considering the impact of A β on neuronal excitability, there are seemingly contradictory findings, potentially explainable through the aforementioned hormetic role of A β (Fig. 4). Whilst low levels of A β can increase dendritic spine density [194], increase the number of docked vesicles [92], enhance glutamate release, promote excitotoxicity, and disrupt calcium homeostasis (particularly in early stages of disease) [7, 35, 225], A β production after synaptic activity could also act via negative feedback to prevent hyperactivity [123]. Indeed, A β can induce spine collapse and synapse loss [231, 274], increase the proportion of silent neurons [35], and disrupt neurotransmitter release via depletion of presynaptic PIP₂ [99]. However, untangling the specific role of A β versus APP, alternative APP-processing products or BACE1

has proven difficult. Both *APP*^{-/-} [243] and *BACE1*^{-/-} [103, 112, 130] mice fail to produce A β and show hypersensitivity to spontaneous and induced seizures. BACE1, however, cleaves a variety of proteins important for normal neuronal function, including seizure protein 6 [206]. Notably, conditional *BACE1* knockout in adult mice does not induce epileptiform activity [264], suggesting BACE1 or A β may play independent roles in the developing versus adult brain. To add further complexity, overexpression of APP, not A β , is responsible for hypersynchronous activity in some AD mouse models [26]. Therefore, clarification of the roles of A β , APP, and BACE1 will be essential to ensure balanced synaptic activity when therapeutically targeting amyloid dysregulation.

Neurogenesis, synaptogenesis, and structural plasticity

The formation of new neurons and synapses is an important process both throughout development and in the adult nervous system. Early studies found that low concentrations of A β promote the survival of primary neurons [278] and have a neurogenic effect on neural progenitor cells [158]. A β ₁₋₄₂ also stimulates neurogenesis of subventricular zone precursors in vivo, raising the hypothesis that the early overstimulation of neurogenesis in AD may result in depletion of the stem cell pool and a decline in basal neurogenesis later in life [238]. Despite showing neurogenic properties, A β is often considered an antagonist to the formation of new synapses. Indeed, high concentrations of oligomeric A β can induce spine collapse [7, 231, 274], and synapse loss has been found to correlate with increased intraneuronal APP [295], plaque-proximal extracellular A β [132, 295], and accumulation of intraneuronal A β [97, 253]. However, long exposure to picomolar A β has also been found to increase the spine density in slice cultures [194]. Similarly, *APP* knockout in hippocampal neurons reduces neuronal branching and synapse formation [239], and *APP*^{-/-} mice show a profound loss of synaptic proteins [53, 228], although loss of sAPP α (a non-amyloidogenic product of APP cleavage) may be a key contributor to this phenotype (reviewed in [47]). BACE1 has also been shown to play a role in normal synapse development, with *BACE1*^{-/-} mice showing a developmental hearing impairment caused by aberrant synaptic organisation in the cochlea [60]. Interestingly, adult wild-type mice treated with BACE1 inhibitors also show a reduction in dendritic spine density and formation [74], whilst BACE1 inhibitor treatment of APP/PS1 mice (which produce excess A β) slowed the rate of synapse loss around plaques [204]. Taken together, it once again seems likely that there is an optimal concentration of A β to maintain synapses, which must be considered when therapeutically targeting A β (Fig. 4).

Tau may also play a role in neuronal development and synaptogenesis. In vitro, stimulation of hippocampal neurons with brain-derived neurotrophic factor (BDNF) normally increases tau expression and spine growth, but tau-shRNA treatment significantly decreases baseline spine numbers and blocks the pro-synaptic response to BDNF [44]. In adult mice, tau-shRNA treatment reduced apical and basal dendrite density, supporting a role for tau in spine formation or maintenance [266]. In *MAPT*^{-/-} mice, new-born granule neurons in the dentate gyrus fail to migrate normally [78, 227], show reduced dendritic length, and have disrupted postsynaptic density (PSD) and mossy fiber terminal formation [197]. Tau also mediates the pro-neurogenic effect of environmental enrichment on adult hippocampal neurogenesis and synaptic integration [197]. Other studies have reported impaired neurogenesis in *MAPT*^{-/-} mice [107], potentially explaining the reduced brain weight reported in some strains [145, 146]. An anti-aggregant tau mouse model shows increased neurogenesis and hippocampal volume [120], whilst tauopathy models frequently show deficits in hippocampal neurogenesis [134], potentially highlighting tau aggregation as a loss-of-function mechanism in this context. Tau knockdown also delays neuronal maturation in primary neurons [54] and induces transcriptional repression of neuronal genes [11], indicative of a potential role of tau in promoting neuronal differentiation. Some studies, however, contradict these findings, reporting increased neurogenesis in tau-deficient animals [50]. Further exploration of the role of tau in adult neurogenesis, and whether this translates to humans, is, therefore, required.

Regulating behaviour

Tau, hyperactivity, anxiety, and sleep

In addition to cognitive deficits, *MAPT*^{-/-} mice show evidence of hyperactivity, as measured by spontaneous locomotion in an open field test [23, 114], and substantially increased rearing behaviour [148]. *MAPT*^{-/-} mice also spend significantly less time in the open arms of elevated Z-mazes and keep to the periphery of open field arenas, indicative of increased anxiety [86]. Tau may also help to regulate circadian behaviours, with *MAPT*^{-/-} mice [41] or *Drosophila* [8], showing major abnormalities in the sleep–wake cycle, including increased wakefulness and disruption to normal circadian activities. Sleep disturbances are commonly reported in ageing and neurodegenerative disorders [281], so understanding how tau alterations impact sleep may be clinically relevant. Interestingly, tauopathy models often show disturbed sleep patterns [122] and hyperactivity [122, 205] phenotypes, raising the possibility that tau mutations

could, for these behaviours, mimic the effect of tau depletion through loss of function.

Tau and the motor system

Another common feature of *MAPT*^{-/-} mice is the appearance of FTD-P17-like motor dysfunction, suggesting that tau loss of function could be partly responsible for Parkinsonism in these individuals [145]. Notably, soluble tau levels in the substantia nigra of the brains of individuals with PD are 44% lower than those observed in age-matched controls, indicating that loss of normal tau may contribute to motor deficits [145]. In mouse studies, a number of groups have reported significant impairment in balance beam or rotarod performance in tau knockouts [114, 145, 146, 157, 164, 186], mice lacking 4R tau [93], and mice treated with tau-shRNA [266]. Additionally, changes in gait [146], reduced locomotion [145, 146], and muscle weakness [114] have been recorded, and many *MAPT*^{-/-} models also show loss of dopaminergic neurons [145, 146, 164]. Interestingly, treatment of *MAPT*^{-/-} mice with L-DOPA rescued motor phenotypes in some models [145, 146], but another study reported a dopamine-independent motor deficit [186]. A recent study postulated that the age-dependent motor deficits observed in their *MAPT*^{-/-} model were due to hypomyelination and degeneration of the sciatic nerve (discussed below), raising further questions about the effect of tau loss of function in the peripheral versus central nervous systems [157]. Interestingly, motor deficits are common in tau-overexpressing transgenic mice [4, 77], and it has been reported that whilst modest overexpression of FTD-P17 mutant tau can improve motor performance in young animals, this progresses to severe paraparesis in later life [183]. In humans, the *MAPT* H1/H1 genotype is also associated with increased risk of neurodegenerative diseases affecting the motor system, such as corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) [108]. Taken together, it seems likely that, in addition to mutations potentially disrupting physiological roles of tau, changes in tau concentration may have a hormetic effect on motor function (Fig. 4). Whilst individuals with AD can develop motor symptoms [155], this is not considered the primary deficit, indicative that the location of tau changes within the brain (e.g., hippocampus versus substantia nigra or motor cortex) and peripheral nervous system is likely an important determinant of symptoms.

Regulation of myelination

Tau is important for normal myelination

Whilst many studies focus on neuronal damage, white matter hyperintensities (evidence of demyelination) are commonly reported in the early stages of AD and other tauopathies and correlate with tau burden [173]. A recent study describes human familial globular glial tauopathy, linked to *MAPT* mutations, that result in extensive tau deposits in oligodendrocytes [73]. Affected individuals show severe demyelination, defective myelin synthesis, and concomitant axonal damage [73]. Coiled bodies of tau in oligodendrocytes and demyelination are also common features of other primary tauopathies such as PSP and CBD [291]. Mouse models of tauopathy frequently demonstrate deficits in myelination, with evidence of filamentous tau inclusions developing in oligodendrocytes [149], resulting in defective myelination of the perforant path [117], spinal cord [149], and sciatic nerve [179]. Tauopathy-induced myelination deficits coincide with increased nerve conduction latency [117], cognitive decline [117], and motor impairments [179]. The mechanism by which tau pathology leads to deficits in myelination has yet to be fully elucidated, but there is evidence that this could represent a loss of normal tau function. Tau is found within oligodendrocytes and Schwann cells under physiological conditions and is upregulated during developmental myelination [159]. siRNA-mediated knockdown of tau impairs oligodendrocyte process outgrowth, reduces myelin basic protein (MBP) expression, and impairs contact with axons in myelinating co-cultures [230]. Oligodendrocyte process outgrowth depends on the recruitment of tau and tubulin to activated Fyn-kinase rafts, with disruption of tau-microtubule binding reducing oligodendrocyte process number and length [129]. Expression of an inducible, truncated tau (which retains the Fyn-binding domain but lacks microtubule-binding capability) in oligodendrocytes induced demyelination and gait abnormalities in mice [160]. *MAPT*^{-/-} mice also show age-dependent degeneration of myelinated fibers, reduced nerve conduction, and progressive hypomyelination [157, 237], resulting in motor [157] and nociceptive [237] impairments. Tau knockdown also restricts recovery after sciatic nerve damage, with mice showing defective myelin debris clearance and severely impaired Schwann cell migration and differentiation [285]. Similarly, *MAPT*^{-/-} mice showed a worse clinical outcome after experimental autoimmune encephalomyelitis (EAE) (a model of demyelinating disease) [277]. Taken together, it seems likely that tau plays a key role in forming, maintaining, and repairing myelin, potentially via the regulation of microtubule dynamics [129]. Tau hyperphosphorylation may disrupt this key function in disease, contributing to

the commonly observed white matter pathology. Whether myelination deficits will become a problem for tau-targeting therapeutics remains to be seen, but caution may be required to ensure normal oligodendrocyte and Schwann cell function is maintained.

A β and its cleavage enzymes may regulate myelination

A recent study reports that low concentrations of A β oligomers can *enhance* oligodendrocyte survival in vitro [215]. A β peptides also induced translation of MBP, promoted oligodendrocyte differentiation, and improved remyelination in demyelinated cerebellar slices [215]. *BACE1*^{-/-} mice show delayed myelination and reduced myelin thickness in the PNS and CNS [110, 280], as well as impaired remyelination of peripheral nerves after injury [109, 111]. However, *BACE1*^{-/-} phenotypes may be A β -independent, relying instead on the cleavage of neuregulins [109], highlighting a potential off-target effect of lowering A β through BACE1 inhibition. Interestingly, BACE1, neuregulin-1, and A β expression increase during myelin repair following ischaemic stroke, suggesting a potential role in the myelin repair process [190]. However, oligomeric A β ₁₋₄₂ can also reduce oligodendrocyte number and induce motor deficits when injected intracerebroventricularly in mice [290]. Interestingly, a recent study has found that the secreted metalloprotease ADAMTS4, located exclusively in oligodendrocytes in adult mice, is responsible for the production of highly amyloidogenic, N-truncated, A β _{4-x} peptides [271]. Further studies will, therefore, be required to elucidate the role of A β peptides and their cleavage enzymes in oligodendrocytes, and to determine whether A β -targeting therapies will be beneficial or detrimental in resolving white matter pathology in disease. Once again, it seems likely that a balance between preventing toxicity and maintaining physiological functions will be required.

A β regulates vasculature

Angiogenesis and A β : a question of balance?

There is mounting evidence that A β plays important roles in regulating vasculature. Studies in post-mortem human brains have found evidence for increased angiogenesis in AD [21, 58], with one study finding that vascular density in the hippocampus positively correlated with A β load [58]. Conversely, other studies have reported *reduced* vascularisation in AD brains [76]. Studies in AD mice found evidence for a dual-staged response to rising A β , with young animals showing increased vascular density compared to wild-type littermates, with reversal of the trend in old mice

[21]. In vitro, A β can inhibit endothelial cell capillary formation in a dose-dependent manner and stimulates capillary degeneration at high concentrations [201]. At low concentrations, however, A β has been found to promote endothelial cell proliferation [27], induce formation of capillary-like structures [27], and increase vessel density in brain slice cultures [64]. In vivo studies using chick [27] or zebrafish embryos [40] and adult zebrafish retinas [51] find that A β peptides increase capillary density and induce formation of sprouting tip cells. *BACE1*^{-/-} mice also show a significant reduction in retinal vascular density [38] and *APP*-deficient zebrafish, or zebrafish treated with a BACE1 inhibitor, have shorter hindbrain vessels with fewer cerebrovascular branches [163]. Crucially, application of human A β rescued the vascular phenotype in both *APP*-deficient and BACE1 inhibitor-treated zebrafish [163], highlighting a primary role of endogenous A β in maintaining normal capillary density.

Whilst low levels of A β seem important for maintaining physiological vascularisation, increasing levels of A β in early AD have been shown to promote *pathological angiogenesis*, resulting in excessive vascularisation and disturbance to normal blood flow [21, 58, 64]. Excessive cleavage of APP, or direct inhibitory action of A β , may overwhelm or inhibit the activity of γ -secretase, thus reducing its availability to cleave Notch proteins, known angiogenesis inhibitors [27, 64]. Indeed, γ -secretase inhibitor treatment increases angiogenesis and vascularisation in a range of model systems [40]. Lowering A β levels, through immunisation against A β [20] or BACE1 inhibition [64], restores normal vascular patterns in AD models. Indeed, a meta-analysis of clinical trials reports that people with AD receiving immunisations against A β ₁₋₄₂, show a significant reduction of endothelial cells and vascular density [20]. In another example of hormesis, either too little or too much A β may result in pathological alterations to capillary density (Fig. 4). Carefully controlling A β concentration will be important to restore and maintain physiological angiogenesis in AD.

A β as a “vascular plug”

Clinical trials targeting A β have unintentionally provided evidence for a further role of A β in the vascular system: repairing leaks in the blood–brain barrier (BBB) [30]. A side effect of a number of active or passive anti-A β immunotherapies has been the appearance of microhaemorrhages and brain oedema [203]. This pattern of pathology, visible by MRI, has been termed “Amyloid-Related Imaging Abnormalities” (ARIA) and has become synonymous with A β immunisation [240]. A meta-analysis of 14 A β -targeting clinical trials reported a fivefold increase in the incidence of ARIA in treated versus placebo AD groups, with many trials showing a dose-dependent effect and increased incidence in *APOE4* carriers [203]. A β immunisation in AD mouse

models [24] and aged mouse lemurs [121] can also induce ARIA-like cerebral microbleeds.

At present, it is not fully understood why removal of A β causes haemorrhages. Deposition of amyloid in blood vessels [cerebral amyloid angiopathy (CAA)] is a common feature of AD [166]. One possibility is that sudden removal of amyloid from blood vessels could compromise vascular integrity, as amyloid may have completely replaced the vessel wall in some instances (grade 2 CAA) [166]. Alternatively, a number of groups have proposed a relationship between A β and blood clotting. Platelets are the primary source of A β within the blood [43] and A β can induce aggregation of platelets [69]. It has been postulated that A β could play a physiological role as a vascular sealant, which could become overactivated with age and disease [30]. The expression of APP and A β rises in response to haemorrhagic damage, such as induction of microhaemorrhages [80] and chronic hypertension [33]. *APP*^{-/-} or *BACE*^{-/-} mice also show increased mortality after ischaemic injury, with severe deficits in reactive blood flow compared to wild-type controls [133]. Taken together, these findings add weight to the hypothesis that A β could serve a crucial role in vascular responses to injury, potentially explaining the appearance of ARIA after A β -immunotherapy. Conversely, high levels of A β can increase BBB permeability, potentially via reducing levels of tight junction proteins [127]. Interestingly, increasing BBB permeability promoted clearance of A β from the brain and improved cognition in a mouse model of AD, indicative of a physiological negative feedback mechanism [127]. Once again, this demonstrates the delicate balance between A β acting to support physiological versus pathological processes that must be considered to design safe, effective therapeutics.

Response to injury

Tau and A β increase after injury: a protective or pathological response?

Increasing evidence demonstrates that the levels of both tau and A β proteins increase following stroke [190], spinal cord injury (SCI) [195, 212] and traumatic brain injury (TBI) [282]. TBI promotes tau aggregation and spreading [67], with levels of tau pathology detected via PET correlating with poor long-term neuropsychiatric outcomes [251]. Whilst increases in tau often correlate with poorer outcome after injury [251], increased soluble A β has been shown to correlate with improved neurological status in individuals with a TBI [29]. Similarly, the formation of A β deposits in demyelinating lesions in people with multiple sclerosis (MS) has been proposed as a potentially protective response to axonal injury [89]. This raises the question of whether

increases in tau and A β after injury serve to promote recovery, or whether they are involved in a detrimental pathological cascade.

A β may promote recovery after brain injury

Attempts to clarify the function of increased A β after injury have produced conflicting results and it is often difficult to separate specific effects of A β from functions of APP, which is known to be upregulated in axons after injury and may have protective functions [100]. Whilst some groups found that *BACE1* knockout or inhibition improves recovery after sciatic nerve injury [72] or TBI [153], others report that *BACE1*^{-/-} mice have impaired remyelination after sciatic nerve lesion [109, 111] and worse functional outcome after SCI [195] or TBI [168]. Interestingly, both *BACE1*^{-/-} and *APP*^{-/-} mice have an increased risk of mortality following cerebral ischaemia, indicating that this is likely a consequence of A β loss [133]. Mannix et al. found that following controlled cortical impact (CCI), functional outcome is worse in *BACE1*^{-/-} mice compared to wild-type mice [168]. A follow-up study demonstrated that motor function (but not spatial memory or histopathology) could be improved by administration of A β ₁₋₄₀ to *BACE1*^{-/-} mice after CCI, demonstrating a potential role for A β in recovery [167]. In the same study, administration of A β to injured wild-type animals *worsened* outcome, demonstrating a hormetic role for A β [167] (Fig. 4). Grant et al. also showed that peripheral administration of A β could reduce paralysis and demyelination in a mouse model of EAE, providing further evidence of a role for A β in promoting recovery after injury [89].

The effect of tau depends on the type of injury induced

Studies exploring the role of tau after injury have also been contradictory. *MAPT*^{-/-} mice suffer worse functional outcome after sciatic nerve injury [285] and EAE [277], reminiscent of tau regulating physiological myelination (discussed earlier). Several studies, however, report that *MAPT*^{-/-} mice are resistant to some functional and cognitive deficits after TBI, although this depends on whether the injury was repetitive [45] and whether short-term or long-term outcomes were measured [256]. A study by Bi et al. found that following experimental stroke, *MAPT*^{-/-} mice were protected from neurological deficits and excitotoxic brain damage [19]. The authors suggested a mechanism for this effect whereby tau normally mediates excitotoxic Ras/ERK signalling by regulating SynGAP1 postsynaptic compartmentalisation [19]. Whilst further

experiments are required in a range of injury models, it seems likely that the positive versus negative effects of targeting tau will depend largely on the type of damage induced and the normal recovery mechanisms required. An apparent role for tau in myelin repair may mean that individuals with AD who have a history of MS, for example, could be at risk of worse outcome after receiving tau-lowering therapies. Similarly, A β -lowering therapies may increase the risk of brain damage in individuals who go on to suffer a TBI, which may be a risk in individuals who frequently suffer falls [260]. Therefore, patient history could be key in assessing the risk for negative outcomes associated with comorbidities, prior to the administration of tau- or A β -targeting therapeutics.

Mitochondria and oxidative stress

Mitochondrial dysfunction is a key component of AD pathology

Mitochondrial dysfunction is an early and important pathogenic feature of AD [98], and both tau and A β have been shown to separately and synergistically affect mitochondrial function [66]. Whilst most studies have examined the pathological effects of tau and A β on mitochondria, there is some evidence that these proteins may also have physiological roles.

A β and tau deposition: cause of, or response to, oxidative damage?

Many studies have found an association between mitochondrial A β deposition and oxidative stress [66, 193]. However, the directionality of the observed events, i.e., whether A β accumulation is a cause of, or response to, oxidative stress, has proven difficult to ascertain. Somewhat counterintuitively, whilst oxidative stress is an early feature of AD, oxidative damage decreases alongside increased A β deposition during AD progression [193]. Notably, neurons containing an NFT show a 40–56% decrease in oxidised nucleosides compared to non-tangle-bearing neurons [193], leading to the proposal that A β and tau may have antioxidant properties [235]. Interestingly, a gene called *saitohin*, located in the intron downstream of exon 9 within the *MAPT* gene, interacts with peroxiredoxin 6, an antioxidant enzyme that protects cells from oxidative damage [79]. Whilst further research is required to explore the interaction of *saitohin* with tau, it seems likely that gene-level changes to *MAPT* may also impact the function of *saitohin*. Therefore, caution may be required when utilising tau- or A β -targeting

therapies, to avoid potential exacerbation of oxidative damage.

Tau as a regulator of mitochondrial mobility and health?

Tau has also been proposed to regulate mitochondrial function. Sapir et al. found that tau knockdown reduced mitochondrial mobility and increased the number of abnormal mitochondria [227]. A recent study reports that tau localises to the outer mitochondrial membrane under physiological conditions, proposing a role for tau in regulating mitochondrial association, and calcium transfer, with the endoplasmic reticulum [48]. However, overexpression of tau can also impair mitochondrial transport [65] and mouse models of tauopathy demonstrate deficits in mitochondrial distribution [135]. These seemingly contradictory results require further exploration and it seems likely that tau expression levels, post-translational modifications, developmental stage, and potential compensation from other MAPs will all impact whether tau serves a physiological or pathological role at the mitochondria.

A β may function as an antimicrobial peptide

The antimicrobial protection/infection hypotheses of AD

In 2002, Robinson and Bishop proposed that A β is normally produced to “bind toxic solutes” with the formation of amyloid plaques being “an efficient means of presenting these toxins to phagocytes” [220]. Since then, a number of groups have built upon the idea of amyloidosis as an innate immune response and have proposed that increased A β deposition, caused by continuous activation of this pathway through recurrent, chronic infection, may lead to the development of AD [182].

A β rises after infection and is associated with pathogens in the CNS

A number of studies have shown that infection with a range of pathogens, including Herpes simplex virus-1 (HSV-1), *Chlamydia pneumoniae* and *Borrelia burgdorferi*, can increase production and deposition of A β in vitro and in vivo, where microbial DNA can be found associated with amyloid plaques (reviewed in [87]). Interestingly, a post-mortem study of individuals who had died from HIV/AIDS found that over half of them possessed extensive

accumulation of A β in the brain, despite their young age (average age of death was 43 years old) [90]. Interestingly, treatment of HSV-1-infected cell cultures with the antiviral agent Acyclovir lowers intracellular A β accumulation and normalises BACE1 expression, leading to the proposal that antiviral therapies may be beneficial for the treatment of AD [162]. It is important to note, however, that human studies linking infections and AD are mostly correlational in nature. Whilst there is considerable evidence for a role of neuroinflammation in the progression of AD [106], it is possible that the increase in microbes in the AD brain is a response to rather than a cause of AD pathology. Break-down of the BBB is common during neurodegenerative disease [248], and this could permit invasion of microbes circulating in the periphery, especially viruses, such as HSV, that are endemic in the population [283].

A β has antimicrobial activity

The increased expression of A β after infection is proposed to be an innate immune response, and there is evidence that A β can act as an antimicrobial peptide (AMP) (reviewed in [87]). Soscia et al. found that A β exhibits antimicrobial action of equal or greater potency than LL-37 (a human antimicrobial peptide) against eight common microbes [236]. Application of A β also decreases the infectivity of HSV-1 [162] in cell lines, and reduces the growth of *Candida albicans*, Gram-negative, and Gram-positive bacteria [138, 236] in culture. In vivo, Kumar et al. found that A β over-expression significantly increases survival in 5xFAD mice infected with *S. Typhimurium*, and in *C. elegans* infected with *C. albicans* and *S. Typhimurium* [138]. The authors suggest that A β acts as an AMP by agglutinating and trapping microbes via the binding of its heparin-binding domain to carbohydrates in microbe cell walls [138]. Alternatively, A β may form cation channels in cell membranes, inducing cell death via calcium dyshomeostasis [126]. Interestingly, *APP*^{-/-} mice show a trend for increased mortality after infection [138] and a common side effect of A β -targeting therapies in clinical trials has been increased incidence of infections [87], although BBB disruption caused by removal of vascular amyloid could also explain this increased vulnerability [240].

Regulation of iron homeostasis

Iron homeostasis may be disrupted in neurodegenerative disorders

A number of groups have postulated that iron dyshomeostasis could contribute to AD and other neurodegenerative diseases [140], with iron accumulation resulting in cellular

oxidative damage, dysfunction, and death via ferroptosis, an iron-dependent form of regulated necrosis [140]. It remains unknown whether iron dyshomeostasis is a cause, or consequence, of neurodegenerative pathology, but there is evidence that tau and APP may play physiological roles in regulating cellular iron transport.

Tau and APP play a role in physiological iron transport

Whilst the role of A β in regulating iron homeostasis is unclear, APP has been proposed to have iron-export ferroxidase activity and interacts with, and stabilises, a major iron transport protein, ferroportin [16, 63]. Indeed, *APP*^{-/-} neurons retain more iron [63] and *APP*^{-/-} mice show vulnerability to oxidative damage from dietary iron [63] and exhibit exaggerated age-dependent iron accumulation in the brain and liver [16]. Tau may also regulate iron transport, likely through mediating transport of APP to ferroportin [145]. Lei et al. found that *MAPT*^{-/-} mice exhibit age-dependent iron accumulation associated with neurodegeneration, cognitive deficits, and parkinsonian-like motor deficits [145]. These deficits were rescued by treatment of aged *MAPT*^{-/-} mice with the iron chelator clioquinol [144]. Interestingly, they also found that tau levels were reduced by ~40% in the substantia nigra of individuals with PD [145], and the authors hypothesise that loss of tau may contribute to the extensive iron accumulation reported in this brain region in PD. The same group reported that lithium-mediated reduction of tau in wild-type mice, or primary cortical neurons, results in iron accumulation in the brain and reduced cellular iron efflux [143]. Taken together, the effects of tau-lowering therapeutics on iron homeostasis should be carefully considered when targeting tau in AD. As iron chelation has been shown to be beneficial in a *MAPT*^{-/-} mouse model [144], potentially detrimental side effects may be avoided by a combinatorial approach targeting both tau and iron dyshomeostasis.

The role of tau and A β in the nucleus

Tau is located at the nucleus and interacts with oligonucleotides

Whilst the majority of tau protein is located in the cytoplasm, there is clear evidence for nuclear association of tau in cell lines [156, 165, 234], primary neurons [11], and in mouse [267] and human [68, 216] brain tissue. Nuclear tau is mostly unphosphorylated [246] and is often localised to the nucleolar border, co-localising with constitutive heterochromatin [169] and ribosomal DNA (rDNA) [226]. In vitro, tau readily binds RNA [31] and DNA [39, 275]. Tau binds the minor groove of DNA, in a manner analogous to histones,

via its proline-rich domain and microtubule-binding domain R2 [39, 275]. Tau's ability to bind nucleic acids is disrupted by hyperphosphorylation [161], raising the possibility that such changes during disease may result in loss of function.

Tau protects DNA from damage

Neurons continuously face the harmful effects of oxidative stress and evidence points to a key role for tau in preventing DNA damage and promoting repair [267]. Cellular stress, induced by heat shock or reactive oxygen species (ROS), results in dephosphorylation of tau, translocation to the nucleus [246, 267] and increases the capacity for tau to bind DNA [246]. In vitro, tau protects DNA from thermal denaturation, DNase digestion, and ROS-mediated damage [39, 275]. Hyperphosphorylation prevents tau from binding DNA, resulting in DNA breakage and deficient repair under experimental stress conditions [161]. Whilst primary neuronal cultures from wild-type mice are resistant to hyperthermic conditions, DNA breaks caused by extensive heat shock become evident in tau-deficient neurons, damage which can be rescued by overexpression of human tau targeted to the nucleus [246]. In vivo, *MAPT*^{-/-} mice show increased DNA fragmentation under physiological conditions and are highly susceptible to DNA breakage after hyperthermic stress [267]. *MAPT*^{-/-} mice also show delayed *repair* of double-strand breaks after heat shock which was especially evident in the CA1 hippocampal subfield [267]. Caution may, therefore, be required to ensure that tau-lowering therapies do not increase neuronal susceptibility to DNA damage.

Tau maintains chromosomal stability

Cells from individuals with *MAPT* mutations consistently show chromosomal aberrations, including breakages, gaps, aneuploidies, and translocations [222]. Interestingly, knocking out one or both copies of tau in murine splenocytes resulted in a marked increase in aneuploidy, indicating that *MAPT* mutations could induce dysfunction via loss of function, potentially through disruption of the mitotic spindle [88]. In *MAPT*^{-/-} neurons, hallmarks of normal pericentromeric heterochromatin (clustering of H3K9me3 and HP1 α) are also disrupted [165, 169], indicating a role for tau in maintaining nucleolar integrity. Pericentromeric chromatin was also found to be disrupted in AD post-mortem brain tissue, further supporting a role for tau loss of function in disease [169].

Tau as a regulator of transcription

In addition to maintaining genomic integrity, tau may also regulate transcription of genes involved in neuronal function.

A recent paper reported that shRNA knockdown of tau in neurons greatly reduced both mRNA and protein levels of VGLUT1 [234]. Overexpressing wild-type tau, or forcing tau translocation to the nucleus, resulted in increased VGLUT1 transcription [234]. Remarkably, this effect was abolished when attempted with P301L-mutant tau, indicating a potential loss-of-function effect of this FTD-associated mutation. Tau has also been implicated in *repressing* transcription of a number of genes implicated in neuronal function [17], with tau depletion, resulting in upregulation of proteins such as BAF-57 (involved in neuron-specific gene repression) [11]. Additionally, tau knockdown alters rDNA transcription, although whether tau normally promotes [226] or represses [165] this process, and the implications for neuronal function, is still under debate. Overall, tau plays many roles at the nucleus and there is evidence for disruption of these functions in disease. Preserving the physiological functions of tau at the nucleus may, therefore, provide therapeutic benefit in tauopathies.

A β at the nucleus - a caution for tau-lowering therapeutics?

Whilst the APP-processing product AICD is frequently associated with the nucleus (reviewed in [47]), a nuclear role for A β has been less forthcoming. Exogenously applied, or transfected, A β can translocate to the nucleus in vitro and is found at the nucleus in adult wild-type or APP/PS1 mice [12]. Some studies have suggested that A β ₁₋₄₂ can regulate transcription, including upregulation of APP and insulin-like growth factor receptors [12, 13]. However, most studies focus on the pathological roles of A β in the nucleus including inducing DNA breaks [244] and increasing chromosome mis-segregation by disrupting physiological tau function [88]. The fact that A β induces DNA damage provides an interesting link between potential A β and tau pathology in disease. Perhaps, increasing A β -mediated DNA damage results in reactionary alterations to tau that become overwhelmed in time. With this in mind, tau-lowering therapeutics without additional targeting of A β may need to be carefully considered to prevent additional DNA damage resulting from the removal of physiological protection.

A β and tau may function as tumour suppressors

Do individuals with AD have reduced incidence of cancer?

An increasing number of studies have reported a striking inverse association between AD and many types of cancer (reviewed in [30]), with one study reporting that the risk

of developing cancer was 50% lower in individuals with AD [188]. This effect is not thought to be simply due to individuals with cancer dying earlier in life, as there is no such inverse correlation with other age-related disorders such as vascular dementia [221]. Of note, a recent paper by Rossi et al. showed that individuals with FTD possessing an *MAPT* mutation have an *increased* risk of developing cancer [223]. Together, such findings warrant exploration of whether tau and A β could function physiologically as tumour suppressors.

A β can act as a tumour suppressor

A β has been proposed to act as a tumour suppressor under a number of experimental conditions [30]. Studies demonstrate that A β can suppress tumour growth [201] and inhibit cancer cell proliferation [202], with A β dimers/trimers being stronger tumour inhibitors than pentadecamers [202]. AD transgenic mice overexpressing A β also demonstrate reduced growth rate of implanted glioma tumours, with the authors proposing that high levels of A β could inhibit neoangiogenesis within the tumour mass [200]. Brothers et al. suggest that A β could also indirectly suppress tumour formation through intercepting oncogenic viruses, or via scavenging free metal ions, restricting availability of micronutrients required for cell proliferation [30]. It is worth noting that the majority of studies investigating A β as a potential tumour suppressor have used supraphysiological concentrations in their models. Therefore, it is difficult to discern whether A β has a role in tumour suppression at physiological concentrations in humans. A recent study found significantly decreased *BACE1* expression in invasive ductal carcinoma, indicating that reduced levels of A β could potentially increase the proliferation rate of this aggressive tumour [284]. Counter-intuitively, *increased* levels of APP have been found in a number of cancers, with worse outcomes associated with higher APP levels (reviewed in [198]). Further research is, therefore, required to elucidate the contribution of A β and its processing pathways to cancer pathogenesis and the potential impacts of A β -targeting therapies on cancer risk.

Loss of tau function may increase tumour incidence

As microtubules are crucial components of the mitotic spindle and regulate the cell cycle [82], it seems plausible that tau could play a role in tumorigenesis. Gargini et al. showed that tau expression levels vary in different cancer types and high tau expression levels correlate with increased patient survival [82]. Another study found that *MAPT* knockdown enhanced cell growth and invasion and suggested that tau may be a tumour-suppressive protein in clear cell renal cell carcinoma [95]. The finding that *MAPT* mutations increase the risk of developing cancer suggests that tau mutations

may result in loss of a tumour-suppressive function [223]. On the other hand, increased *MAPT* expression correlates with poor prognosis and taxane (a microtubule-stabilising drug) resistance in gastric cancer [180]. It appears that tau may have different effects depending on the cancer type being studied, highlighting the heterogeneous nature of cancer and the need for further research. As with A β , any potential for increased risk of cancer must be carefully assessed when designing tau-targeting therapeutics for AD.

Glucose metabolism

Dysregulation of insulin signalling in AD

Diabetes is a well-established risk factor for developing AD [152]. Insulin receptors are densely expressed in the hippocampus, frontal cortex, and entorhinal cortex [49], with insulin playing key roles in a number of crucial CNS processes such as synaptogenesis, synaptic remodelling [46], and regulation of memory [175]. The link between impaired insulin signalling and cognitive decline has been demonstrated in humans and animal models [25, 49]. Indeed, impaired brain glucose metabolism is an early characteristic of AD, with one study reporting that up to 81% of individuals with AD had either type 2 diabetes or impaired fasting glucose, an indicator of prediabetes [119]. Whilst direct connections between glucose metabolism, tau, and A β have been made, it is important to highlight that the association between AD and diabetes could be, at least in part, due to diabetes-related blood vessel damage given the strong epidemiological links between many vascular risk factors and AD [152, 176].

Tau regulates normal glucose metabolism

Marciniak et al. reported that *MAPT*^{-/-} mice exhibit insulin resistance in the hippocampus, suggesting that tau plays a normal role in the cellular response to insulin, a function that may be lost in AD [170]. The authors propose a mechanism, whereby tau normally interacts with PTEN, a phosphatase that inhibits insulin signalling, reducing its activity [170]. Tau is expressed in the pancreas [296], and *MAPT*^{-/-} mice have been shown to develop pancreatic β cell dysfunction and glucose intolerance [279]. A recent imaging study in humans found that A β affected tau-glucose metabolism associations [2]. This study reported that during normal ageing, small increases in tau are associated with *increased* glucose metabolism, but large accumulations of hyperphosphorylated tau associated with A β deposition correlated instead with hypometabolism, suggestive of a hormetic function for tau (Fig. 4), or A β -mediated dysregulation of normal tau function [2]. Interestingly, data from genome-wide

association studies have shown that the *MAPT* H1 haplotype is associated with increased glucose intolerance in humans [170]. Taken together, tau likely plays a role in the regulation of homeostatic glucose metabolism. How this changes during disease, for example by loss of function caused by A β accumulation, or the potential effects of tau-targeting therapies on insulin signalling, requires further exploration.

A β -processing enzymes regulate insulin signalling

Whilst A β has been proposed to dysregulate insulin signalling [25], there is mounting evidence that its cleavage enzyme, BACE1, which is strongly expressed in the pancreas [298], plays crucial physiological roles in glucose homeostasis. Indeed, *BACE1*^{-/-} mice show impaired insulin expression in the pancreas [104] and siRNA-mediated BACE1 knockdown significantly reduces insulin mRNA and protein in insulinoma cells [104]. However, another study reports that *BACE1*^{-/-} mice have enhanced insulin sensitivity [177]. Notably, hyperglycaemia increases BACE1-mediated production of A β [142], indicative of a potentially vicious cycle between amyloid and glucose dysregulation. This also highlights the likely contribution of diseases such as diabetes mellitus to AD development and emphasises the potential of nutritional intervention strategies as a means of treating and preventing AD.

Conclusion

From molecular interactions with DNA to influencing complex behaviour, the physiological roles of tau (Fig. 5) and A β (Fig. 6) are multifaceted, dynamic, and at times, contradictory. This review emphasises the complexity of untangling physiology from pathology, as well as the wide-reaching implications, for both the brain and body, that can be induced by subtle protein alterations. Whilst the range of functions which we discuss are diverse, common themes emerge:

- The functions of tau and A β are influenced by their location. Shifts within the cell, expression in different cells or locations within the body, can alter the roles that these proteins play, whether they are beneficial or harmful, and how therapeutic treatments will influence function.
- Different isoforms, aggregation status, and post-translational modifications can dramatically alter the function of tau and A β .
- The concentrations of tau and A β are crucial for regulating physiological versus pathological function. This “hormetic nature”, where too much or too little protein causes functional deficits, raises the likelihood of a “therapeutic sweet spot” where the physiologically optimal





Fig. 5 A schematic representation of the suggested physiological roles of tau in the brain and body. Created with <https://biorender.com/>

Fig. 6 A schematic representation of the suggested physiological roles of A β in the brain and body. Created with <https://biorender.com/>



concentrations lie, outside of which may result in damage (Fig. 4).

- AD is likely a combination of both gain- and loss-of-function phenotypes. Physiological responses can become hijacked to become toxic, detrimental functions can appear, or normal functions can be lost during disease-related changes.
- Contradictory findings are common in the literature. The potential for developmental compensation in constitutive knockouts, as well as experimental differences in factors such as age, sex, and environment, will all impact outcome. Future studies testing multiple timepoints, acute versus constitutive knockdown, different genetic backgrounds, mixed-sex cohorts, and increasing comparisons between animal and human tissue will greatly clarify genuine phenotypes from experimental artefacts.

With the above in mind, a meticulous approach to therapeutic development is crucial. Therapies must balance potentially detrimental effects of targeting tau (Table 1) and A β (Table 2) with the benefits of disrupting pathology. Targeting treatments early in the disease cascade, considering the individual's medical history (such as previous injury and comorbidities), engaging with modifiable lifestyle risk factors and the use of combinatorial therapies will likely be important to obtain the best outcome for individuals. By understanding the functions of tau and A β in health, we can gain greater insight into their contribution to disease. Such research will be vital for the development of safe and effective therapeutic strategies.

Acknowledgements Sarah Kent is a Translational Neuroscience PhD student funded by Wellcome (108890/Z/15/Z). Tara Spires-Jones receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 681181), the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK, and industrial collaborative partners (none of whom had any influence over the current paper). Claire Durrant is funded by ARUK Race Against Dementia-Dyson fellowship (RADF2019A-001).

Author contributions SAK wrote and edited the manuscript and designed the figures. TLS-J wrote and edited the manuscript. CSD planned, wrote and edited the manuscript, and designed the figures.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Adalbert R, Milde S, Durrant C, Ando K, Stygelbout V, Yilmaz Z et al (2018) Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport. *Neurobiol Aging* 68:68–75. <https://doi.org/10.1016/j.neurobiolaging.2018.03.033>

2. Adams JN, Lockhart SN, Li L, Jagust WJ (2019) Relationships between tau and glucose metabolism reflect alzheimer's disease pathology in cognitively normal older adults. *Cereb Cortex N Y NY* 29:1997–2009. <https://doi.org/10.1093/cercor/bhy078>
3. Ahmed T, Van der Jeugd A, Blum D, Galas M-C, D'Hooge R, Buee L et al (2014) Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. *Neurobiol Aging* 35:2474–2478. <https://doi.org/10.1016/j.neurobiolaging.2014.05.005>
4. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K et al (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human p301s tau protein. *J Neurosci* 22:9340–9351. <https://doi.org/10.1523/JNEUROSCI.22-21-09340.2002>
5. Alzheimer's Association (2019) 2019 Alzheimer's disease facts and figures. *Alzheimers Dement* 15:321–387. <https://doi.org/10.1016/j.jalz.2019.01.010>
6. Amos LA (2004) Microtubule structure and its stabilisation. *Org Biomol Chem* 2:2153–2160. <https://doi.org/10.1039/B403634D>
7. Arbel-Ornath M, Hudry E, Boivin JR, Hashimoto T, Takeda S, Kuchibhotla KV et al (2017) Soluble oligomeric amyloid- β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. *Mol Neurodegener* 12:27. <https://doi.org/10.1186/s13024-017-0169-9>
8. Arnes M, Alaniz ME, Karam CS, Cho JD, Lopez G, Javitch JA et al (2019) Role of tau protein in remodeling of circadian neuronal circuits and sleep. *Front Aging Neurosci* 11:320. <https://doi.org/10.3389/fnagi.2019.00320>
9. Ballatore C, Lee VM-Y, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nat Rev Neurosci* 8:663–672. <https://doi.org/10.1038/nrn2194>
10. Barbier P, Zejneli O, Martinho M, Lasorsa A, Belle V, Smet-Nocca C et al (2019) Role of tau as a microtubule-associated protein: structural and functional aspects. *Front Aging Neurosci*. <https://doi.org/10.3389/fnagi.2019.00204>
11. de Barreda EG, Dawson HN, Vitek MP, Avila J (2010) Tau deficiency leads to the upregulation of BAF-57, a protein involved in neuron-specific gene repression. *FEBS Lett* 584:2265–2270. <https://doi.org/10.1016/j.febslet.2010.03.032>
12. Barucker C, Harmeier A, Weiske J, Fauler B, Albring KF, Prokop S et al (2014) Nuclear translocation uncovers the amyloid peptide A β 42 as a regulator of gene transcription. *J Biol Chem* 289:20182–20191. <https://doi.org/10.1074/jbc.M114.564690>
13. Barucker C, Sommer A, Beckmann G, Eravci M, Harmeier A, Schipke CG et al (2015) Alzheimer amyloid peptide a β 42 regulates gene expression of transcription and growth factors. *J Alzheimers Dis JAD* 44:613–624. <https://doi.org/10.3233/JAD-141902>
14. Bear MF, Malenka RC (1994) Synaptic plasticity: LTP and LTD. *Curr Opin Neurobiol* 4:389–399. [https://doi.org/10.1016/0959-4388\(94\)90101-5](https://doi.org/10.1016/0959-4388(94)90101-5)
15. Beevers JE, Lai MC, Collins E, Booth HDE, Zambon F, Parkkinen L et al (2017) MAPT genetic variation and neuronal maturity alter isoform expression affecting axonal transport in ipsiderived dopamine neurons. *Stem Cell Rep* 9:587–599. <https://doi.org/10.1016/j.stemcr.2017.06.005>
16. Belaidi AA, Gunn AP, Wong BX, Ayton S, Appukuttan AT, Roberts BR et al (2018) Marked age-related changes in brain iron homeostasis in amyloid protein precursor knockout mice. *Neurother J Am Soc Exp Neurother* 15:1055–1062. <https://doi.org/10.1007/s13311-018-0656-x>
17. Benhelli-Mokrani H, Mansuroglu Z, Chauderlier A, Albaud B, Gentien D, Sommer S et al (2018) Genome-wide identification of genic and intergenic neuronal DNA regions bound by Tau protein under physiological and stress conditions. *Nucleic Acids Res* 46:11405–11422. <https://doi.org/10.1093/nar/gky929>
18. Besag FM (2017) Epilepsy in patients with autism: links, risks and treatment challenges. *Neuropsychiatr Dis Treat* 14:1–10. <https://doi.org/10.2147/NDT.S120509>
19. Bi M, Gladbach A, van Eersel J, Ittner A, Przybyla M, van Hummel A et al (2017) Tau exacerbates excitotoxic brain damage in an animal model of stroke. *Nat Commun* 8:473. <https://doi.org/10.1038/s41467-017-00618-0>
20. Biron KE, Dickstein DL, Gopaul R, Fenninger F, Jefferies WA (2013) Cessation of neoangiogenesis in alzheimer's disease follows amyloid-beta immunization. *Sci Rep* 3:1354. <https://doi.org/10.1038/srep01354>
21. Biron KE, Dickstein DL, Gopaul R, Jefferies WA (2011) Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. *PLoS ONE* 6:e23789. <https://doi.org/10.1371/journal.pone.0023789>
22. Biswas S, Kalil K (2018) The microtubule-associated protein tau mediates the organization of microtubules and their dynamic exploration of actin-rich lamellipodia and filopodia of cortical growth cones. *J Neurosci* 38:291–307. <https://doi.org/10.1523/JNEUROSCI.2281-17.2017>
23. Biundo F, Prete DD, Zhang H, Arancio O, D'Adamio L (2018) A role for tau in learning, memory and synaptic plasticity. *Sci Rep* 8:1–13. <https://doi.org/10.1038/s41598-018-21596-3>
24. Blockx I, Einstein S, Guns P-J, Van Audekerke J, Guglielmetti C, Zago W et al (2016) Monitoring blood-brain barrier integrity following amyloid- β immunotherapy using gadolinium-enhanced mri in a pdapp mouse model. *J Alzheimers Dis JAD* 54:723–735. <https://doi.org/10.3233/JAD-160023>
25. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel J-C, Decker H et al (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A β oligomers. *J Clin Invest* 122:1339–1353. <https://doi.org/10.1172/JCI57256>
26. Born HA, Kim J-Y, Savjani RR, Das P, Dabaghian YA, Guo Q et al (2014) Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzheimer's disease. *J Neurosci Off J Soc Neurosci* 34:3826–3840. <https://doi.org/10.1523/JNEUROSCI.5171-13.2014>
27. Boscolo E, Folin M, Nico B, Grandi C, Mangieri D, Longo V et al (2007) β amyloid angiogenic activity in vitro and in vivo. *Int J Mol Med* 19:581–587. <https://doi.org/10.3892/ijmm.19.4.581>
28. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol (Berl)* 82:239–259. <https://doi.org/10.1007/BF00308809>
29. Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N et al (2008) Amyloid-beta dynamics correlate with neurological status in the injured human brain. *Science* 321:1221–1224. <https://doi.org/10.1126/science.1161591>
30. Brothers HM, Gosztyla ML, Robinson SR (2018) The physiological roles of amyloid- β peptide hint at new ways to treat Alzheimer's Disease. *Front Aging Neurosci*. <https://doi.org/10.3389/fnagi.2018.00118>
31. Bryan JB, Nagle BW, Doenges KH (1975) Inhibition of tubulin assembly by RNA and other polyanions: evidence for a required protein. *Proc Natl Acad Sci USA* 72:3570–3574
32. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF et al (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. *J Neurosci Off J Soc Neurosci* 25:7709–7717. <https://doi.org/10.1523/JNEUROSCI.2177-05.2005>
33. Bueche CZ, Hawkes C, Garz C, Vielhaber S, Attems J, Knight RT et al (2014) Hypertension drives parenchymal β -amyloid

- accumulation in the brain parenchyma. *Ann Clin Transl Neurol* 1:124–129. <https://doi.org/10.1002/acn3.27>
34. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A et al (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. *J Biol Chem* 267:546–554
 35. Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B et al (2012) Critical role of soluble amyloid- β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci* 109:8740–8745. <https://doi.org/10.1073/pnas.1206171109>
 36. Caceres A, Kosik KS (1990) Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. *Nature* 343:461–463. <https://doi.org/10.1038/343461a0>
 37. Caceres A, Potrebic S, Kosik KS (1991) The effect of tau antisense oligonucleotides on neurite formation of cultured cerebellar macroneurons. *J Neurosci Off J Soc Neurosci* 11:1515–1523
 38. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q et al (2012) β -Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. *EMBO Mol Med* 4:980–991. <https://doi.org/10.1002/emmm.201101084>
 39. Camero S, Benítez MJ, Barrantes A, Ayuso JM, Cuadros R, Avila J et al (2014) Tau protein provides DNA with thermodynamic and structural features which are similar to those found in histone-DNA complex. *J Alzheimers Dis JAD* 39:649–660. <https://doi.org/10.3233/JAD-131415>
 40. Cameron DJ, Galvin C, Alkam T, Sidhu H, Ellison J, Luna S et al (2012) Alzheimer's-related peptide amyloid- β plays a conserved role in angiogenesis. *PLoS ONE* 7:e39598. <https://doi.org/10.1371/journal.pone.0039598>
 41. Cantero JL, Hita-Yañez E, Moreno-Lopez B, Portillo F, Rubio A, Avila J (2010) Tau protein role in sleep-wake cycle. *J Alzheimers Dis JAD* 21:411–421. <https://doi.org/10.3233/JAD-2010-100285>
 42. Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M et al (2012) The mechanism of γ -Secretase dysfunction in familial Alzheimer disease. *EMBO J* 31:2261–2274. <https://doi.org/10.1038/emboj.2012.79>
 43. Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid beta-peptide in human blood. *Biochem Biophys Res Commun* 213:96–103. <https://doi.org/10.1006/bbrc.1995.2103>
 44. Chen Q, Zhou Z, Zhang L, Wang Y, Zhang Y, Zhong M et al (2012) Tau protein is involved in morphological plasticity in hippocampal neurons in response to BDNF. *Neurochem Int* 60:233–242. <https://doi.org/10.1016/j.neuint.2011.12.013>
 45. Cheng JS, Craft R, Yu G-Q, Ho K, Wang X, Mohan G et al (2014) Tau reduction diminishes spatial learning and memory deficits after mild repetitive traumatic brain injury in mice. *PLoS ONE* 9:e115765. <https://doi.org/10.1371/journal.pone.0115765>
 46. Chiu S-L, Chen C-M, Cline HT (2008) Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. *Neuron* 58:708–719. <https://doi.org/10.1016/j.neuron.2008.04.014>
 47. Chow VW, Mattson MP, Wong PC, Gleichmann M (2010) An overview of APP processing enzymes and products. *Neuromolecular Med* 12:1–12. <https://doi.org/10.1007/s12017-009-8104-z>
 48. Cieri D, Vicario M, Vallese F, D'Orsi B, Berto P, Grinzato A et al (2018) Tau localises within mitochondrial sub-compartments and its caspase cleavage affects ER-mitochondria interactions and cellular Ca²⁺ handling. *Biochim Biophys Acta BBA* 1864:3247–3256. <https://doi.org/10.1016/j.bbadis.2018.07.011>
 49. Craft S, Baker LD, Montine TJ, Minooshima S, Watson GS, Claxton A et al (2012) Intranasal insulin therapy for alzheimer disease and amnesic mild cognitive impairment. *Arch Neurol* 69:29–38. <https://doi.org/10.1001/archneurol.2011.233>
 50. Criado-Marrero M, Sabbagh JJ, Jones MR, Chaput D, Dickey CA, Blair LJ (2020) Hippocampal neurogenesis is enhanced in adult tau deficient mice. *Cells*. <https://doi.org/10.3390/cells9010210>
 51. Cunvong K, Huffmire D, Ethell DW, Cameron DJ (2013) Amyloid- β increases capillary bed density in the adult zebrafish retina. *Invest Ophthalmol Vis Sci* 54:1516–1521. <https://doi.org/10.1167/iovs.12-10821>
 52. Davies C, Spire-Jones TL (2018) Complementing tau: new data show that the complement system is involved in degeneration in tauopathies. *Neuron* 100:1267–1269. <https://doi.org/10.1016/j.neuron.2018.12.003>
 53. Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O'Dowd G et al (1999) Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. *Neuroscience* 90:1–13. [https://doi.org/10.1016/s0306-4522\(98\)00410-2](https://doi.org/10.1016/s0306-4522(98)00410-2)
 54. Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP (2001) Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. *J Cell Sci* 114:1179–1187
 55. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS et al (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. *Nature* 398:518–522. <https://doi.org/10.1038/19083>
 56. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. *Ann Neurol* 27:457–464
 57. Derby CA, Katz MJ, Lipton RB, Hall CB (2017) Trends in dementia incidence in a birth cohort analysis of the Einstein Aging Study. *JAMA Neurol* 74:1345–1351. <https://doi.org/10.1001/jamaneuro.2017.1964>
 58. Desai BS, Schneider JA, Li J-L, Carvey PM, Hendey B (2009) Evidence of angiogenic vessels in Alzheimer's disease. *J Neural Transm Vienna Austria* 116:587–597. <https://doi.org/10.1007/s00702-009-0226-9>
 59. DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR et al (2013) Antisense reduction of tau in adult mice protects against seizures. *J Neurosci* 33:12887–12897. <https://doi.org/10.1523/JNEUROSCI.2107-13.2013>
 60. Dierich M, Hartmann S, Dietrich N, Moeser P, Brede F, Johnson Chacko L et al (2019) β -Secretase BACE1 is required for normal cochlear function. *J Neurosci* 39:9013–9027. <https://doi.org/10.1523/JNEUROSCI.0028-19.2019>
 61. Dixit R, Ross JL, Goldman YE, Holzbaur ELF (2008) Differential regulation of dynein and kinesin motor proteins by tau. *Science* 319:1086–1089. <https://doi.org/10.1126/science.1152993>
 62. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. *Mol Biol Cell* 3:1141–1154
 63. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikke K et al (2010) Iron-export ferroxidase activity of β -amyloid precursor protein is inhibited by zinc in Alzheimer's disease. *Cell* 142:857–867. <https://doi.org/10.1016/j.cell.2010.08.014>
 64. Durrant CS, Ruscher K, Sheppard O, Coleman MP, Özen I (2020) Beta secretase 1-dependent amyloid precursor protein processing promotes excessive vascular sprouting through NOTCH3 signalling. *Cell Death Dis* 11:1–15. <https://doi.org/10.1038/s41419-020-2288-4>
 65. Ebnet A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E-M et al (1998) Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's Disease. *J Cell Biol* 143:777–794

66. Eckert A, Schmitt K, Götz J (2011) Mitochondrial dysfunction the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid- β toxicity. *Alzheimers Res Ther* 3:15. <https://doi.org/10.1186/alzrt74>
67. Edwards G, Zhao J, Dash PK, Soto C, Moreno-Gonzalez I (2019) Traumatic brain injury induces tau aggregation and spreading. *J Neurotrauma* 37:80–92. <https://doi.org/10.1089/neu.2018.6348>
68. Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y et al (2018) Tau protein disrupts nucleocytoplasmic transport in Alzheimer's disease. *Neuron* 99:925–940. e7. <https://doi.org/10.1016/j.neuron.2018.07.039>
69. Elaskalani O, Khan I, Morici M, Matthyssen C, Sabale M, Martins RN et al (2018) Oligomeric and fibrillar amyloid beta 42 induce platelet aggregation partially through GPVI. *Platelets* 29:415–420. <https://doi.org/10.1080/09537104.2017.1401057>
70. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T et al (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. *Science* 248:1122–1124. <https://doi.org/10.1126/science.2111583>
71. Evans W, Fung HC, Steele J, Eerola J, Tienari P, Pittman A et al (2004) The tau H2 haplotype is almost exclusively Caucasian in origin. *Neurosci Lett* 369:183–185. <https://doi.org/10.1016/j.neulet.2004.05.119>
72. Farah MH, Pan BH, Hoffman PN, Ferraris D, Tsukamoto T, Nguyen T et al (2011) Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. *J Neurosci* 31:5744–5754. <https://doi.org/10.1523/JNEUROSCI.6810-10.2011>
73. Ferrer I, Andrés-Benito P, Zelaya MV, Aguirre MEE, Carmona M, Ausín K et al (2020) Familial globular glial tauopathy linked to MAPT mutations: molecular neuropathology and seeding capacity of a prototypical mixed neuronal and glial tauopathy. *Acta Neuropathol (Berl)* 139:735–771. <https://doi.org/10.1007/s00401-019-02122-9>
74. Filser S, Ovsepian SV, Masana M, Blazquez-Llorca L, Brandt Elvang A, Volbracht C et al (2015) Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. *Biol Psychiatry* 77:729–739. <https://doi.org/10.1016/j.biopsych.2014.10.013>
75. Fischer I, Baas PW (2020) Resurrecting the mysteries of big tau. *Trends Neurosci* 43:493–504. <https://doi.org/10.1016/j.tins.2020.04.007>
76. Fischer VW, Siddiqi A, Yusufaly Y (1990) Altered angioarchitecture in selected areas of brains with Alzheimer's disease. *Acta Neuropathol (Berl)* 79:672–679. <https://doi.org/10.1007/bf00294246>
77. Frank S, Clavaguera F, Tolnay M (2007) Tauopathy models and human neuropathology: similarities and differences. *Acta Neuropathol (Berl)* 115:39–53. <https://doi.org/10.1007/s00401-007-0291-9>
78. Fuster-Matanzo A, de Barreda EG, Dawson HN, Vitek MP, Avila J, Hernández F (2009) Function of tau protein in adult newborn neurons. *FEBS Lett* 583:3063–3068. <https://doi.org/10.1016/j.febslet.2009.08.017>
79. Gao L, Tse S-W, Conrad C, Andreadis A (2005) Saitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin 6. *J Biol Chem* 280:39268–39272. <https://doi.org/10.1074/jbc.M506116200>
80. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C et al (2011) Cerebrovascular lesions induce transient β -amyloid deposition. *Brain J Neurol* 134:3697–3707. <https://doi.org/10.1093/brain/awr300>
81. Garcia-Osta A, Alberini CM (2009) Amyloid beta mediates memory formation. *Learn Mem* 16:267–272. <https://doi.org/10.1101/lm.1310209>
82. Gargini R, Segura-Collar B, Sánchez-Gómez P (2019) Novel functions of the neurodegenerative-related gene tau in cancer. *Front Aging Neurosci*. <https://doi.org/10.3389/fnagi.2019.00231>
83. Gilley J, Seereeram A, Ando K, Mosely S, Andrews S, Kerschenshneider M et al (2012) Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse. *Neurobiol Aging* 33:621.e1–621.e15. <https://doi.org/10.1016/j.neurobiolaging.2011.02.014>
84. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC (1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. *Science* 235:877–880. <https://doi.org/10.1126/science.3810169>
85. Golovyashkina N, Penazzi L, Ballatore C, Smith AB, Bakota L, Brandt R (2015) Region-specific dendritic simplification induced by A β , mediated by tau via dysregulation of microtubule dynamics: a mechanistic distinct event from other neurodegenerative processes. *Mol Neurodegener* 10:60. <https://doi.org/10.1186/s13024-015-0049-0>
86. Gonçalves RA, Wijesekara N, Fraser PE, De Felice FG (2020) Behavioral Abnormalities in Knockout and Humanized Tau Mice. *Front Endocrinol*. <https://doi.org/10.3389/fendo.2020.00124>
87. Gosztyla ML, Brothers HM, Robinson SR (2018) Alzheimer's amyloid- β is an antimicrobial peptide: a review of the evidence. *J Alzheimers Dis JAD* 62:1495–1506. <https://doi.org/10.3233/JAD-171133>
88. Granic A, Padmanabhan J, Norden M, Potter H (2010) Alzheimer A β peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: requirement for tau and APP. *Mol Biol Cell* 21:511–520. <https://doi.org/10.1091/mbc.E09-10-0850>
89. Grant JL, Ghosn EEB, Axtell RC, Herges K, Kuipers HF, Woodling NS et al (2012) Reversal of paralysis and reduced inflammation from peripheral administration of β -amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. *Sci Transl Med* 4:145ra105. <https://doi.org/10.1126/scitranslmed.3004145>
90. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. *AIDS Lond Engl* 19:407–411. <https://doi.org/10.1097/01.aids.0000161770.06158.5c>
91. Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, Checler F et al (1999) Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β -amyloid peptides. *Proc Natl Acad Sci* 96:742–747. <https://doi.org/10.1073/pnas.96.2.742>
92. Gulisano W, Melone M, Ripoli C, Tropea MR, Puma DDL, Giunta S et al (2019) Neuromodulatory action of picomolar extracellular a β 42 oligomers on presynaptic and postsynaptic mechanisms underlying synaptic function and memory. *J Neurosci* 39:5986–6000. <https://doi.org/10.1523/JNEUROSCI.0163-19.2019>
93. Gumucio A, Lannfelt L, Nilsson LN (2013) Lack of exon 10 in the murine tau gene results in mild sensorimotor defects with aging. *BMC Neurosci* 14:148. <https://doi.org/10.1186/1471-2202-14-148>
94. Guo T, Noble W, Hanger DP (2017) Roles of tau protein in health and disease. *Acta Neuropathol (Berl)* 133:665–704. <https://doi.org/10.1007/s00401-017-1707-9>
95. Han X, Sekino Y, Babasaki T, Goto K, Inoue S, Hayashi T et al (2020) Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma. *Urol Oncol* 38:605.e9–605.e17. <https://doi.org/10.1016/j.urolonc.2020.02.010>
96. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T et al (1994) Altered microtubule organization in small-calibre

- axons of mice lacking tau protein. *Nature* 369:488–491. <https://doi.org/10.1038/369488a0>
97. Harwell CS, Coleman MP (2016) Synaptophysin depletion and intraneuronal A β in organotypic hippocampal slice cultures from huAPP transgenic mice. *Mol Neurodegener* 11:44. <https://doi.org/10.1186/s13024-016-0110-7>
 98. Hauptmann S, Keil U, Scherping I, Bonert A, Eckert A, Müller WE (2006) Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. *Exp Gerontol* 41:668–673. <https://doi.org/10.1016/j.exger.2006.03.012>
 99. He Y, Wei M, Wu Y, Qin H, Li W, Ma X et al (2019) Amyloid β oligomers suppress excitatory transmitter release via presynaptic depletion of phosphatidylinositol-4,5-bisphosphate. *Nat Commun* 10:1193. <https://doi.org/10.1038/s41467-019-09114-z>
 100. Hefter D, Draguhn A (2017) APP as a protective factor in acute neuronal insults. *Front Mol Neurosci*. <https://doi.org/10.3389/fnmol.2017.00022>
 101. Hellström-Lindahl E, Viitanen M, Marutle A (2009) Comparison of A β levels in the brain of familial and sporadic Alzheimer's disease. *Neurochem Int* 55:243–252. <https://doi.org/10.1016/j.neuint.2009.03.007>
 102. Hernández-Vega A, Braun M, Scharrel L, Jahnel M, Wegmann S et al (2017) Local nucleation of microtubule bundles through tubulin concentration into a condensed tau phase. *Cell Rep* 20:2304–2312. <https://doi.org/10.1016/j.celrep.2017.08.042>
 103. Hitt BD, Jaramillo TC, Chetkovich DM, Vassar R (2010) BACE1 $^{-/-}$ mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. *Mol Neurodegener* 5:31. <https://doi.org/10.1186/1750-1326-5-31>
 104. Hoffmeister A, Tuennemann J, Sommerer I, Mössner J, Rittger A, Schleinitz D et al (2013) Genetic and biochemical evidence for a functional role of BACE1 in the regulation of insulin mRNA expression. *Obesity* 21:E626–E633. <https://doi.org/10.1002/oby.20482>
 105. Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG et al (2013) Tau loss attenuates neuronal network hyperexcitability in mouse and *Drosophila* genetic models of epilepsy. *J Neurosci Off J Soc Neurosci* 33:1651–1659. <https://doi.org/10.1523/JNEUROSCI.3191-12.2013>
 106. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S et al (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* 352:712–716. <https://doi.org/10.1126/science.aad8373>
 107. Hong X-P, Peng C-X, Wei W, Tian Q, Liu Y-H, Yao X-Q et al (2010) Essential role of tau phosphorylation in adult hippocampal neurogenesis. *Hippocampus* 20:1339–1349. <https://doi.org/10.1002/hipo.20712>
 108. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S et al (2001) Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. *Neurology* 56:1702–1706. <https://doi.org/10.1212/wnl.56.12.1702>
 109. Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB et al (2008) Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. *FASEB J* 22:2970–2980. <https://doi.org/10.1096/fj.08-106666>
 110. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD et al (2006) Bace1 modulates myelination in the central and peripheral nervous system. *Nat Neurosci* 9:1520–1525. <https://doi.org/10.1038/nn1797>
 111. Hu X, Hu J, Dai L, Trapp B, Yan R (2015) Axonal and schwann cell BACE1 is equally required for remyelination of peripheral nerves. *J Neurosci* 35:3806–3814. <https://doi.org/10.1523/JNEUROSCI.5207-14.2015>
 112. Hu X, Zhou X, He W, Yang J, Xiong W, Wong P et al (2010) BACE1 deficiency causes altered neuronal activity and neurodegeneration. *J Neurosci* 30:8819–8829. <https://doi.org/10.1523/JNEUROSCI.1334-10.2010>
 113. van Hummel A, Bi M, Ippati S, van der Hoven J, Volkerling A, Lee WS et al (2016) No overt deficits in aged tau-deficient C57Bl/6. Mapt^{tm1(EGFP)Kit} GFP knockin mice. *PLoS ONE* 11:e0163236. <https://doi.org/10.1371/journal.pone.0163236>
 114. Ikegami S, Harada A, Hirokawa N (2000) Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. *Neurosci Lett* 279:129–132. [https://doi.org/10.1016/s0304-3940\(99\)00964-7](https://doi.org/10.1016/s0304-3940(99)00964-7)
 115. Iqbal K, Grundke-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS et al (1986) Defective brain microtubule assembly in Alzheimer's disease. *Lancet Lond Engl* 2:421–426. [https://doi.org/10.1016/s0140-6736\(86\)92134-3](https://doi.org/10.1016/s0140-6736(86)92134-3)
 116. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J et al (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. *Cell* 142:387–397. <https://doi.org/10.1016/j.cell.2010.06.036>
 117. Jackson J, Bianco G, Rosa AO, Cowan K, Bond P, Anichtchik O et al (2018) White matter tauopathy: transient functional loss and novel myelin remodeling. *Glia* 66:813–827. <https://doi.org/10.1002/glia.23286>
 118. Janning D, Igaev M, Sündermann F, Brühmann J, Beutel O, Heinisch JJ et al (2014) Single-molecule tracking of tau reveals fast kiss-and-hop interaction with microtubules in living neurons. *Mol Biol Cell* 25:3541–3551. <https://doi.org/10.1091/mbc.E14-06-1099>
 119. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. *Diabetes* 53:474–481. <https://doi.org/10.2337/diabetes.53.2.474>
 120. Joseph M, Anglada-Huguet M, Paesler K, Mandelkow E, Mandelkow E-M (2017) Anti-aggregant tau mutant promotes neurogenesis. *Mol Neurodegener* 12:88. <https://doi.org/10.1186/s1302-4-017-0230-8>
 121. Joseph-Mathurin N, Dorieux O, Trouche SG, Boutajangout A, Kraska A, Fontès P et al (2013) Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. *Neurobiol Aging* 34:2613–2622. <https://doi.org/10.1016/j.neurobiolaging.2013.05.013>
 122. Jul P, Volbracht C, de Jong IEM, Helboe L, Elvang AB, Pedersen JT (2016) Hyperactivity with agitative-like behavior in a mouse tauopathy model. *J Alzheimers Dis JAD* 49:783–795. <https://doi.org/10.3233/JAD-150292>
 123. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T et al (2003) APP processing and synaptic function. *Neuron* 37:925–937. [https://doi.org/10.1016/s0896-6273\(03\)00124-7](https://doi.org/10.1016/s0896-6273(03)00124-7)
 124. Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson KR, Song Y et al (2011) Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. *J Neurosci Off J Soc Neurosci* 31:9858–9868. <https://doi.org/10.1523/JNEUROSCI.0560-11.2011>
 125. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH et al (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature* 325:733–736. <https://doi.org/10.1038/325733a0>
 126. Kawahara M (2010) Neurotoxicity of β -amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis. *Curr Pharm Des* 16:2779–2789. <https://doi.org/10.2174/138161210793176545>
 127. Keaney J, Walsh DM, O'Malley T, Hudson N, Crosbie DE, Loftus T et al (2015) Autoregulated paracellular clearance of amyloid- β across the blood-brain barrier. *Sci Adv* 1:e1500472. <https://doi.org/10.1126/sciadv.1500472>

128. Kimura T, Whitcomb DJ, Jo J, Regan P, Piers T, Heo S et al (2014) Microtubule-associated protein tau is essential for long-term depression in the hippocampus. *Philos Trans R Soc Lond B Biol Sci* 369:20130144. <https://doi.org/10.1098/rstb.2013.0144>
129. Klein C, Kramer E-M, Cardine A-M, Schraven B, Brandt R, Trotter J (2002) Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau. *J Neurosci Off J Soc Neurosci* 22:698–707
130. Kobayashi D, Zeller M, Cole T, Buttini M, McConlogue L, Sinha S et al (2008) BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. *Neurobiol Aging* 29:861–873. <https://doi.org/10.1016/j.neurobiolaging.2007.01.002>
131. Kobayashi S, Tanaka T, Soeda Y, Takashima A (2019) Enhanced tau protein translation by hyper-excitation. *Front Aging Neurosci* 11:322. <https://doi.org/10.3389/fnagi.2019.00322>
132. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M et al (2009) Oligomeric amyloid associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. *Proc Natl Acad Sci* 106:4012–4017. <https://doi.org/10.1073/pnas.0811698106>
133. Koike MA, Lin AJ, Pham J, Nguyen E, Yeh JJ, Rahimian R et al (2012) APP knockout mice experience acute mortality as the result of ischemia. *PLoS ONE* 7:e42665. <https://doi.org/10.1371/journal.pone.0042665>
134. Komuro Y, Xu G, Bhaskar K, Lamb BT (2015) Human tau expression reduces adult neurogenesis in a mouse model of tauopathy. *Neurobiol Aging* 36:2034–2042. <https://doi.org/10.1016/j.neurobiolaging.2015.03.002>
135. Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI et al (2011) Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. *Am J Pathol* 179:2071–2082. <https://doi.org/10.1016/j.ajpath.2011.07.004>
136. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proc Natl Acad Sci USA* 83:4044–4048
137. Ksiezak-Reding H, Binder LI, Yen SH (1988) Immunochemical and biochemical characterization of tau proteins in normal and Alzheimer's disease brains with Alz 50 and Tau-1. *J Biol Chem* 263:7948–7953
138. Kumar DKV, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J et al (2016) Amyloid- β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. *Sci Transl Med* 8:34072. <https://doi.org/10.1126/scitranslmed.aaf1059>
139. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T et al (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid- β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. *J Neurosci* 25:11693–11709. <https://doi.org/10.1523/JNEUROSCI.2766-05.2005>
140. Lane DJR, Ayton S, Bush AI (2018) Iron and Alzheimer's disease: an update on emerging mechanisms. *J Alzheimers Dis JAD* 64:S379–S395. <https://doi.org/10.3233/JAD-179944>
141. Lee G, Neve RL, Kosik KS (1989) The microtubule binding domain of tau protein. *Neuron* 2:1615–1624. [https://doi.org/10.1016/0896-6273\(89\)90050-0](https://doi.org/10.1016/0896-6273(89)90050-0)
142. Lee HJ, Ryu JM, Jung YH, Lee S-J, Kim JY, Lee SH et al (2016) High glucose upregulates BACE1-mediated A β production through ROS-dependent HIF-1 α and LXR α /ABCA1-regulated lipid raft reorganization in SK-N-MC cells. *Sci Rep*. <https://doi.org/10.1038/srep36746>
143. Lei P, Ayton S, Appukuttan AT, Moon S, Duce JA, Volitakis I et al (2017) Lithium suppression of tau induces brain iron accumulation and neurodegeneration. *Mol Psychiatry* 22:396–406. <https://doi.org/10.1038/mp.2016.96>
144. Lei P, Ayton S, Appukuttan AT, Volitakis I, Adlard PA et al (2015) Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. *Neurobiol Dis* 81:168–175. <https://doi.org/10.1016/j.nbd.2015.03.015>
145. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK et al (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. *Nat Med* 18:291–295. <https://doi.org/10.1038/nm.2613>
146. Lei P, Ayton S, Moon S, Zhang Q, Volitakis I, Finkelstein DI et al (2014) Motor and cognitive deficits in aged tau knockout mice in two background strains. *Mol Neurodegener* 9:29. <https://doi.org/10.1186/1750-1326-9-29>
147. Li L, Fothergill T, Hutchins BI, Dent EW, Kalil K (2014) Wnt5a evokes cortical axon outgrowth and repulsive guidance by tau mediated reorganization of dynamic microtubules. *Dev Neurobiol* 74:797–817. <https://doi.org/10.1002/dneu.22102>
148. Li Z, Hall AM, Kelinske M, Roberson ED (2014) Seizure resistance without parkinsonism in aged mice after tau reduction. *Neurobiol Aging* 35:2617–2624. <https://doi.org/10.1016/j.neurobiolaging.2014.05.001>
149. Lin W-L, Zehr C, Lewis J, Hutton M, Yen S-H, Dickson DW (2005) Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau. *J Neurocytol* 34:397–410. <https://doi.org/10.1007/s11068-006-8726-0>
150. Liu CA, Lee G, Jay DG (1999) Tau is required for neurite outgrowth and growth cone motility of chick sensory neurons. *Cell Motil* 43:232–242. [https://doi.org/10.1002/\(SICI\)1097-0169\(1999\)43:3<232::AID-CM6>3.0.CO;2-7](https://doi.org/10.1002/(SICI)1097-0169(1999)43:3<232::AID-CM6>3.0.CO;2-7)
151. Liu L, Ding L, Rovere M, Wolfe MS, Selkoe DJ (2019) A cellular complex of BACE1 and γ -secretase sequentially generates A β from its full-length precursor. *J Cell Biol* 218:644–663. <https://doi.org/10.1083/jcb.201806205>
152. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D et al (2017) Dementia prevention, intervention, and care. *The Lancet* 390:2673–2734. [https://doi.org/10.1016/S0140-6736\(17\)31363-6](https://doi.org/10.1016/S0140-6736(17)31363-6)
153. Loane DJ, Pocivavsek A, Moussa CE-H, Thompson R, Matsuoka Y et al (2009) Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. *Nat Med* 15:377–379. <https://doi.org/10.1038/nm.1940>
154. Lombardo S, Chiacchiaretta M, Tarr A, Kim W, Cao T, Sigal G et al (2019) BACE1 partial deletion induces synaptic plasticity deficit in adult mice. *Sci Rep*. <https://doi.org/10.1038/s41598-019-56329-7>
155. Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. *Cell* 179:312–339. <https://doi.org/10.1016/j.cell.2019.09.001>
156. Loomis PA, Howard TH, Castleberry RP, Binder LI (1990) Identification of nuclear tau isoforms in human neuroblastoma cells. *Proc Natl Acad Sci USA* 87:8422–8426
157. Lopes S, Lopes A, Pinto V, Guimarães MR, Sardinha VM, Duarte-Silva S et al (2016) Absence of tau triggers age-dependent sciatic nerve morphofunctional deficits and motor impairment. *Aging Cell* 15:208–216. <https://doi.org/10.1111/acer.12391>
158. López-Toledano MA, Shelanski ML (2004) Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. *J Neurosci Off J Soc Neurosci* 24:5439–5444. <https://doi.org/10.1523/JNEUROSCI.0974-04.2004>
159. LoPresti P (2002) Regulation and differential expression of tau mRNA isoforms as oligodendrocytes mature in vivo: implications for myelination. *Glia* 37:250–257. <https://doi.org/10.1002/glia.10035>

160. LoPresti P (2015) Inducible expression of a truncated form of tau in oligodendrocytes elicits gait abnormalities and a decrease in myelin: implications for selective CNS degenerative diseases. *Neurochem Res* 40:2188–2199. <https://doi.org/10.1007/s11064-015-1707-x>
161. Lu Y, He H-J, Zhou J, Miao J-Y, Lu J, He Y-G et al (2013) Hyperphosphorylation results in tau dysfunction in DNA folding and protection. *J Alzheimers Dis* 37:551–563. <https://doi.org/10.3233/JAD-130602>
162. Lukiw WJ, Cui JG, Yuan LY, Bhattacharjee PS, Corkern M, Clement C et al (2010) Acyclovir or A β 42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells. *NeuroReport* 21:922–927. <https://doi.org/10.1097/WNR.0b013e32833da51a>
163. Luna S, Cameron DJ, Ethell DW (2013) Amyloid- β and APP deficiencies cause severe cerebrovascular defects: important work for an old villain. *PLoS ONE* 8:e75052. <https://doi.org/10.1371/journal.pone.0075052>
164. Ma Q-L, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M et al (2014) Loss of MAP function leads to hippocampal synapse loss and deficits in the morris water maze with aging. *J Neurosci* 34:7124–7136. <https://doi.org/10.1523/JNEUROSCI.3439-13.2014>
165. Maina MB, Bailey LJ, Wagih S, Biasetti L, Pollack SJ, Quinn JP et al (2018) The involvement of tau in nucleolar transcription and the stress response. *Acta Neuropathol Commun* 6:70. <https://doi.org/10.1186/s40478-018-0565-6>
166. Mann DMA, Davidson YS, Robinson AC, Allen N, Hashimoto T, Richardson A et al (2018) Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease. *Acta Neuropathol (Berl)* 136:569–587. <https://doi.org/10.1007/s00401-018-1866-3>
167. Mannix RC, Zhang J, Berglass J, Qui J, Whalen MJ (2013) Beneficial effect of amyloid beta after controlled cortical impact. *Brain Inj* 27:743–748. <https://doi.org/10.3109/02699052.2013.771797>
168. Mannix RC, Zhang J, Park J, Lee C, Whalen MJ (2011) Detrimental effect of genetic inhibition of B-site APP-cleaving enzyme 1 on functional outcome after controlled cortical impact in young adult mice. *J Neurotrauma* 28:1855–1861. <https://doi.org/10.1089/neu.2011.1759>
169. Mansuroglu Z, Benhelli-Mokrani H, Marcato V, Sultan A, Violet M, Chauderlier A et al (2016) Loss of Tau protein affects the structure, transcription and repair of neuronal pericentromeric heterochromatin. *Sci Rep* 6:33047. <https://doi.org/10.1038/srep33047>
170. Marciniak E, Leboucher A, Caron E, Ahmed T, Tailleur A, Dumont J et al (2017) Tau deletion promotes brain insulin resistance. *J Exp Med* 214:2257–2269. <https://doi.org/10.1084/jem.20161731>
171. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA* 82:4245–4249. <https://doi.org/10.1073/pnas.82.12.4245>
172. Mazzone G, Menichelli A, Fabretto A, Cattaruzza T, Manganotti P (2018) A new MAPT deletion in a case of speech apraxia leading to corticobasal syndrome. *Neurocase* 24:140–144. <https://doi.org/10.1080/13554794.2018.1492729>
173. McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, Johnson M et al (2015) Cortical tau load is associated with white matter hyperintensities. *Acta Neuropathol Commun*. <https://doi.org/10.1186/s40478-015-0240-0>
174. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement J Alzheimers Assoc* 7:263–269. <https://doi.org/10.1016/j.jalz.2011.03.005>
175. McNay EC, Ong CT, McCrimmon RJ, Cresswell J, Bogan JS, Sherwin RS (2010) Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. *Neurobiol Learn Mem* 93:546–553. <https://doi.org/10.1016/j.nlm.2010.02.002>
176. Meakin PJ, Coull BM, Tuharska Z, McCaffery C, Akoumianakis I, Antoniadis C et al (2020) Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction. *J Clin Invest*. <https://doi.org/10.1172/JCI122237>
177. Meakin PJ, Harper AJ, Hamilton DL, Gallagher J, McNeilly AD, Burgess LA et al (2012) Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. *Biochem J* 441:285–296. <https://doi.org/10.1042/BJ20110512>
178. Mendez M, Lim G (2003) Seizures in elderly patients with dementia: epidemiology and management. *Drugs Aging* 20:791–803. <https://doi.org/10.2165/00002512-200320110-00001>
179. Merchán-Rubira J, Sebastián-Serrano Á, Díaz-Hernández M, Avila J, Hernández F (2019) Peripheral nervous system effects in the PS19 tau transgenic mouse model of tauopathy. *Neurosci Lett* 698:204–208. <https://doi.org/10.1016/j.neulet.2019.01.031>
180. Mimori K, Sadanaga N, Yoshikawa Y, Ishikawa K, Hashimoto M, Tanaka F et al (2006) Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. *Br J Cancer* 94:1894–1897. <https://doi.org/10.1038/sj.bjc.6603182>
181. Miyasaka T, Sato S, Tatebayashi Y, Takashima A (2010) Microtubule destruction induces tau liberation and its subsequent phosphorylation. *FEBS Lett* 584:3227–3232. <https://doi.org/10.1016/j.febslet.2010.06.014>
182. Moir RD, Lathe R, Tanzi RE (2018) The antimicrobial protection hypothesis of Alzheimer's disease. *Alzheimers Dement* 14:1602–1614. <https://doi.org/10.1016/j.jalz.2018.06.3040>
183. Morgan D, Munireddy S, Alamed J, DeLeon J, Diamond DM, Bickford P et al (2008) Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice. *J Alzheimers Dis* 15:605–614
184. Mori H, Takio K, Ogawara M, Selkoe DJ (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. *J Biol Chem* 267:17082–17086
185. Morley JE, Farr SA, Banks WA, Johnson SN, Yamada KA, Xu L (2010) A physiological role for amyloid-beta protein: enhancement of learning and memory. *J Alzheimers Dis* 19:441–449. <https://doi.org/10.3233/JAD-2009-1230>
186. Morris M, Hamto P, Adame A, Devidze N, Masliah E, Mucke L (2013) Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. *Neurobiol Aging* 34:1523–1529. <https://doi.org/10.1016/j.neurobiolaging.2012.12.003>
187. Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM (1996) Alterations in tau protein metabolism during normal aging. *Dement Basel Switz* 7:95–103. <https://doi.org/10.1159/000106861>
188. Musicco M, Adorni F, Di Santo S, Prinelli F, Pettenati C, Caltagirone C et al (2013) Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. *Neurology* 81:322–328. <https://doi.org/10.1212/WNL.0b013e31829c5ec1>
189. Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA (1986) Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. *Mol Brain Res* 1:271–280. [https://doi.org/10.1016/0169-328X\(86\)90033-1](https://doi.org/10.1016/0169-328X(86)90033-1)
190. Nguyen T-VV, Hayes M, Zbesko JC, Frye JB, Congrove NR, Belichenko NP et al (2018) Alzheimer's associated amyloid and

- tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementia. *Acta Neuropathol Commun* 6:100. <https://doi.org/10.1186/s40478-018-0603-4>
191. Nieto A, de Garcini EM, Avila J (1989) Altered levels of microtubule proteins in brains of Alzheimer's disease patients. *Acta Neuropathol (Berl)* 78:47–51. <https://doi.org/10.1007/BF00687401>
 192. Niewidok B, Igaev M, Sündermann F, Janning D, Bakota L, Brandt R (2016) Presence of a carboxy-terminal pseudorepeat and disease-like pseudohyperphosphorylation critically influence tau's interaction with microtubules in axon-like processes. *Mol Biol Cell* 27:3537–3549. <https://doi.org/10.1091/mbc.E16-06-0402>
 193. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK et al (2001) Oxidative damage is the earliest event in Alzheimer disease. *J Neuropathol Exp Neurol* 60:759–767. <https://doi.org/10.1093/jnen/60.8.759>
 194. Ortiz-Sanz C, Gaminde-Blasco A, Valero J, Bakota L, Brandt R, Zugaza JL et al (2020) Early effects of A β oligomers on dendritic spine dynamics and arborization in hippocampal neurons. *Front Synaptic Neurosci*. <https://doi.org/10.3389/fnsyn.2020.00002>
 195. Pajoohesh-Ganji A, Burns MP, Pal-Ghosh S, Tadvalkar G, Hokenbury NG, Stepp MA et al (2014) Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury. *Brain Res* 1560:73–82. <https://doi.org/10.1016/j.brainres.2014.02.049>
 196. Pallas-Bazarrá N, Draffin J, Cuadros R, Antonio Esteban J, Avila J (2019) Tau is required for the function of extrasynaptic NMDA receptors. *Sci Rep*. <https://doi.org/10.1038/s41598-019-45547-8>
 197. Pallas-Bazarrá N, Jurado-Arjona J, Navarrete M, Esteban JA, Hernández F, Ávila J et al (2016) Novel function of tau in regulating the effects of external stimuli on adult hippocampal neurogenesis. *EMBO J* 35:1417–1436. <https://doi.org/10.15252/embj.201593518>
 198. Pandey P, Sliker B, Peters HL, Tuli A, Herskovitz J, Smits K et al (2016) Amyloid precursor protein and amyloid precursor-like protein 2 in cancer. *Oncotarget* 7:19430–19444. <https://doi.org/10.18632/oncotarget.7103>
 199. Papegaey A, Eddarkaoui S, Deramecourt V, Fernandez-Gomez F-J, Pantano P, Obriot H et al (2016) Reduced tau protein expression is associated with frontotemporal degeneration with progranulin mutation. *Acta Neuropathol Commun*. <https://doi.org/10.1186/s40478-016-0345-0>
 200. Paris D, Ganey N, Banasiak M, Laporte V, Patel N, Mullan M et al (2010) Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease. *J Neurosci Off J Soc Neurosci* 30:11251–11258. <https://doi.org/10.1523/JNEUROSCI.2586-10.2010>
 201. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S et al (2004) Inhibition of angiogenesis by Abeta peptides. *Angiogenesis* 7:75–85. <https://doi.org/10.1023/B:AGEN.0000037335.17717.bf>
 202. Pavliukeviciene B, Zentelyte A, Jankunec M, Valiuliene G, Talaikis M, Navakauskiene R et al (2019) Amyloid β oligomers inhibit growth of human cancer cells. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0221563>
 203. Penninkilampi R, Brothers HM, Eslick GD (2017) Safety and Efficacy of Anti-Amyloid- β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis. *J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol* 12:194–203. <https://doi.org/10.1007/s11481-016-9722-5>
 204. Peters F, Salihoglu H, Rodrigues E, Herzog E, Blume T, Filser S et al (2018) BACE1 inhibition more effectively suppresses initiation than progression of β -amyloid pathology. *Acta Neuropathol (Berl)* 135:695–710. <https://doi.org/10.1007/s00401-017-1804-9>
 205. Pickett EK, Herrmann AG, McQueen J, Abt K, Dando O, Tulloch J et al (2019) Amyloid beta and tau cooperate to cause reversible behavioral and transcriptional deficits in a model of Alzheimer's disease. *Cell Rep* 29:3592–3604.e5. <https://doi.org/10.1016/j.celrep.2019.11.044>
 206. Pignoni M, Wanngren J, Kuhn P-H, Munro KM, Gunnarsen JM, Takeshima H et al (2016) Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. *Mol Neurodegener* 11:67. <https://doi.org/10.1186/s13024-016-0134-z>
 207. Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP (2013) Physiological release of endogenous tau is stimulated by neuronal activity. *EMBO Rep* 14:389–394. <https://doi.org/10.1038/embo.2013.15>
 208. Prezel E, Elie A, Delaroché J, Stoppin-Mellet V, Bosc C, Serre L et al (2018) Tau can switch microtubule network organizations: from random networks to dynamic and stable bundles. *Mol Biol Cell* 29:154–165. <https://doi.org/10.1091/mbc.E17-06-0429>
 209. Puzzo D, Argyrousi EK, Staniszewski A, Zhang H, Calcagno E, Zuccarello E et al (2020) Tau is not necessary for amyloid-beta-induced synaptic and memory impairments. *J Clin Invest*. <https://doi.org/10.1172/JCI137040>
 210. Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F et al (2011) Endogenous amyloid- β is necessary for hippocampal synaptic plasticity and memory. *Ann Neurol* 69:819–830. <https://doi.org/10.1002/ana.22313>
 211. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A et al (2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. *J Neurosci Off J Soc Neurosci* 28:14537–14545. <https://doi.org/10.1523/JNEUROSCI.2692-08.2008>
 212. Qi Z, Wang G, Xia P, Hou T, Zhou H, Wang T et al (2016) Effects of microtubule-associated protein tau expression on neural stem cell migration after spinal cord injury. *Neural Regen Res* 11:332–337. <https://doi.org/10.4103/1673-5374.177744>
 213. Qiang L, Sun X, Austin TO, Muralidharan H, Jean DC, Liu M et al (2018) Tau does not stabilize axonal microtubules but rather enables them to have long labile domains. *Curr Biol CB* 28:2181–2189.e4. <https://doi.org/10.1016/j.cub.2018.05.045>
 214. Qiang L, Yu W, Andreadis A, Luo M, Baas PW (2006) Tau protects microtubules in the axon from severing by katanin. *J Neurosci* 26:3120–3129. <https://doi.org/10.1523/JNEUROSCI.5392-05.2006>
 215. Quintela-López T, Ortiz-Sanz C, Serrano-Regal MP, Gaminde-Blasco A, Valero J, Baleriola J et al (2019) A β oligomers promote oligodendrocyte differentiation and maturation via integrin β 1 and Fyn kinase signaling. *Cell Death Dis* 10:1–16. <https://doi.org/10.1038/s41419-019-1636-8>
 216. Rady RM, Zinkowski RP, Binder LI (1995) Presence of tau in isolated nuclei from human brain. *Neurobiol Aging* 16:479–486. [https://doi.org/10.1016/0197-4580\(95\)00023-8](https://doi.org/10.1016/0197-4580(95)00023-8)
 217. Ramirez-Rios S, Denarier E, Prezel E, Vinit A, Stoppin-Mellet V, Devred F et al (2016) Tau antagonizes end-binding protein tracking at microtubule ends through a phosphorylation-dependent mechanism. *Mol Biol Cell* 27:2924–2934. <https://doi.org/10.1091/mbc.E16-01-0029>
 218. Regan P, Piers T, Yi J-H, Kim D-H, Huh S, Park SJ et al (2015) Tau phosphorylation at serine 396 residue is required for hippocampal LTD. *J Neurosci Off J Soc Neurosci* 35:4804–4812. <https://doi.org/10.1523/JNEUROSCI.2842-14.2015>
 219. Roberson ED, Scarce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science* 316:750–754. <https://doi.org/10.1126/science.1141736>

220. Robinson SR, Bishop GM (2002) A β as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. *Neurobiol Aging* 23:1051–1072. [https://doi.org/10.1016/S0197-4580\(01\)00342-6](https://doi.org/10.1016/S0197-4580(01)00342-6)
221. Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP et al (2010) Cancer linked to Alzheimer disease but not vascular dementia. *Neurology* 74:106–112. <https://doi.org/10.1212/WNL.0b013e3181c91873>
222. Rossi G, Conconi D, Panzeri E, Redaelli S, Piccoli E, Paoletta L et al (2013) Mutations in MAPT gene cause chromosome instability and introduce copy number variations widely in the genome. *J Alzheimers Dis JAD* 33:969–982. <https://doi.org/10.3233/JAD-2012-121633>
223. Rossi G, Redaelli V, Contiero P, Fabiano S, Tagliabue G, Perego P et al (2018) Tau mutations serve as a novel risk factor for cancer. *Cancer Res* 78:3731–3739. <https://doi.org/10.1158/0008-5472.CAN-17-3175>
224. Rovelet-Lecrux A, Lecourtis M, Thomas-Anterion C, Ber IL, Brice A, Frebourg T et al (2009) Partial deletion of the MAPT gene: A novel mechanism of FTDP-17. *Hum Mutat* 30:E591–E602. <https://doi.org/10.1002/humu.20979>
225. Russell CL, Semerdjieva S, Empson RM, Austen BM, Beesley PW, Alifragis P (2012) Amyloid- β Acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. *PLoS ONE* 7:e43201. <https://doi.org/10.1371/journal.pone.0043201>
226. Samra EB, Buhagiar-Labarchède G, Machon C, Guitton J, Onclercq-Delic R et al (2017) A role for Tau protein in maintaining ribosomal DNA stability and cytidine deaminase-deficient cell survival. *Nat Commun* 8:1–14. <https://doi.org/10.1038/s41467-017-00633-1>
227. Sapir T, Frotscher M, Levy T, Mandelkow E-M, Reiner O (2012) Tau's role in the developing brain: implications for intellectual disability. *Hum Mol Genet* 21:1681–1692. <https://doi.org/10.1093/hmg/ddr603>
228. Seabrook GR, Smith DW, Bowery BJ, Easter A, Reynolds T, Fitzjohn SM et al (1999) Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. *Neuropharmacology* 38:349–359. [https://doi.org/10.1016/S0028-3908\(98\)00204-4](https://doi.org/10.1016/S0028-3908(98)00204-4)
229. Seblova D, Quiroga ML, Fors S, Johnell K, Lövdén M, de Leon AP et al (2018) Thirty-year trends in dementia: a nationwide population study of Swedish inpatient records. *Clin Epidemiol* 10:1679–1693. <https://doi.org/10.2147/CLEP.S178955>
230. Seiberlich V, Bauer NG, Schwarz L, Ffrench-Constant C, Goldbaum O, Richter-Landsberg C (2015) Downregulation of the microtubule associated protein tau impairs process outgrowth and myelin basic protein mRNA transport in oligodendrocytes. *Glia* 63:1621–1635. <https://doi.org/10.1002/glia.22832>
231. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid- β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. *J Neurosci* 27:2866–2875. <https://doi.org/10.1523/JNEUROSCI.4970-06.2007>
232. Shaw-Smith C, Pittman AM, Willatt L, Martin H, Rickman L, Gribble S et al (2006) Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. *Nat Genet* 38:1032–1037. <https://doi.org/10.1038/ng1858>
233. Siahhaan V, Krattenmacher J, Hyman AA, Diez S, Hernández-Vega A et al (2019) Kinetically distinct phases of tau on microtubules regulate kinesin motors and severing enzymes. *Nat Cell Biol* 21:1086–1092. <https://doi.org/10.1038/s41556-019-0374-6>
234. Siano G, Varisco M, Caiazza MC, Quercioli V, Mainardi M, Ippolito C et al (2019) Tau modulates VGluT1 expression. *J Mol Biol* 431:873–884. <https://doi.org/10.1016/j.jmb.2019.01.023>
235. Smith MA, Casadesus G, Joseph JA, Perry G (2002) Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. *Free Radic Biol Med* 33:1194–1199. [https://doi.org/10.1016/S0891-5849\(02\)01021-3](https://doi.org/10.1016/S0891-5849(02)01021-3)
236. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B et al (2010) The Alzheimer's disease-associated amyloid β -protein is an antimicrobial peptide. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0009505>
237. Sotiropoulos I, Lopes AT, Pinto V, Lopes S, Carlos S, Duarte-Silva S et al (2014) Selective impact of Tau loss on nociceptive primary afferents and pain sensation. *Exp Neurol* 261:486–493. <https://doi.org/10.1016/j.expneurol.2014.07.008>
238. Sotthibundhu A, Li Q-X, Thangnipon W, Coulson EJ (2009) A β (1–42) stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor. *Neurobiol Aging* 30:1975–1985. <https://doi.org/10.1016/j.neurobiolaging.2008.02.004>
239. Southam KA, Stennard F, Pavez C, Small DH (2019) Knockout of Amyloid β Protein Precursor (APP) expression alters synaptogenesis, neurite branching and axonal morphology of hippocampal neurons. *Neurochem Res* 44:1346–1355. <https://doi.org/10.1007/s11064-018-2512-0>
240. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC et al (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. *Lancet Neurol* 11:241–249. [https://doi.org/10.1016/S1474-4422\(12\)70015-7](https://doi.org/10.1016/S1474-4422(12)70015-7)
241. Spires-Jones TL, Attems J, Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. *Acta Neuropathol (Berl)* 134:187–205. <https://doi.org/10.1007/s00401-017-1709-7>
242. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow E-M (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. *J Cell Biol* 156:1051–1063. <https://doi.org/10.1083/jcb.200108057>
243. Steinbach JP, Müller U, Leist M, Li ZW, Nicotera P, Aguzzi A (1998) Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice. *Cell Death Differ* 5:858–866. <https://doi.org/10.1038/sj.cdd.4400391>
244. Suberbielle E, Sanchez PE, Kravitz AV, Wang X, Ho K, Eilertson K et al (2013) Physiological brain activity causes DNA double strand breaks in neurons — exacerbation by amyloid- β . *Nat Neurosci* 16:613–621. <https://doi.org/10.1038/nn.3356>
245. Sudo H, Baas PW (2011) Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases. *Hum Mol Genet* 20:763–778. <https://doi.org/10.1093/hmg/ddq521>
246. Sultan A, Nessler F, Violet M, Bégard S, Loyens A, Talahari S et al (2011) Nuclear tau, a key player in neuronal DNA protection. *J Biol Chem* 286:4566–4575. <https://doi.org/10.1074/jbc.M110.199976>
247. Sündermann F, Fernandez M-P, Morgan RO (2016) An evolutionary roadmap to the microtubule-associated protein MAP Tau. *BMC Genom*. <https://doi.org/10.1186/s12864-016-2590-9>
248. Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood–brain barrier breakdown in Alzheimer's disease and other neurodegenerative disorders. *Nat Rev Neurol* 14:133–150. <https://doi.org/10.1038/nrneuro.2017.188>
249. Tai C, Chang C-W, Yu G-Q, Lopez I, Yu X, Wang X et al (2020) Tau reduction prevents key features of autism in mouse models. *Neuron*. <https://doi.org/10.1016/j.neuron.2020.01.038>
250. Tai H-C, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT (2012) The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome

- system. *Am J Pathol* 181:1426–1435. <https://doi.org/10.1016/j.ajpath.2012.06.033>
251. Takahata K, Kimura Y, Sahara N, Koga S, Shimada H, Ichise M et al (2019) PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury. *Brain J Neurol* 142:3265–3279. <https://doi.org/10.1093/brain/awz238>
 252. Takei Y, Teng J, Harada A, Hirokawa N (2000) Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. *J Cell Biol* 150:989–1000. <https://doi.org/10.1083/jcb.150.5.989>
 253. Tampellini D, Rahman N, Gallo EF, Huang Z, Dumont M, Capetillo-Zarate E et al (2009) Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. *J Neurosci Off J Soc Neurosci* 29:9704–9713. <https://doi.org/10.1523/JNEUROSCI.2292-09.2009>
 254. Tan DCS, Yao S, Ittner A, Bertz J, Ke YD, Ittner LM et al (2018) Generation of a new tau knockout (tau Δ ex1) line using CRISPR/Cas9 genome editing in mice. *J Alzheimers Dis* 62:571–578. <https://doi.org/10.3233/JAD-171058>
 255. Tan R, Lam AJ, Tan T, Han J, Nowakowski DW, Vershinin M et al (2019) Microtubules gate tau condensation to spatially regulate microtubule functions. *Nat Cell Biol* 21:1078–1085. <https://doi.org/10.1038/s41556-019-0375-5>
 256. Tan XL, Zheng P, Wright DK, Sun M, Brady RD, Liu S et al (2020) The genetic ablation of tau improves long-term, but not short-term, functional outcomes after experimental traumatic brain injury in mice. *Brain Inj* 34:131–139. <https://doi.org/10.1080/02699052.2019.1667539>
 257. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML et al (1987) Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. *Science* 235:880–884. <https://doi.org/10.1126/science.2949367>
 258. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. *Ann Neurol* 30:572–580. <https://doi.org/10.1002/ana.410300410>
 259. Tharp WG, Sarkar IN (2013) Origins of amyloid- β . *BMC Genomics* 14:290. <https://doi.org/10.1186/1471-2164-14-290>
 260. Thompson HJ, McCormick WC, Kagan SH (2006) Traumatic brain injury in older adults: epidemiology, outcomes, and future implications. *J Am Geriatr Soc* 54:1590–1595. <https://doi.org/10.1111/j.1532-5415.2006.00894.x>
 261. Tint I, Slaughter T, Fischer I, Black MM (1998) Acute inactivation of tau has no effect on dynamics of microtubules in growing axons of cultured sympathetic neurons. *J Neurosci Off J Soc Neurosci* 18:8660–8673
 262. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A et al (2015) Tissue-based map of the human proteome. *Science*. <https://doi.org/10.1126/science.1260419>
 263. Varela MC, Krepischi-Santos ACV, Paz JA, Knijnenburg J, Szuhai K, Rosenberg C et al (2006) A 17q21.31 microdeletion encompassing the MAPT gene in a mentally impaired patient. *Cytogenet Genome Res* 114:89–92. <https://doi.org/10.1159/000091934>
 264. Vassar R (2019) Implications for BACE1 inhibitor clinical trials: adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus. *J Prev Alzheimers Dis* 6:78–84. <https://doi.org/10.14283/jpad.2019.3>
 265. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P et al (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science* 286:735–741. <https://doi.org/10.1126/science.286.5440.735>
 266. Velazquez R, Ferreira E, Tran A, Turner EC, Belfiore R, Branca C et al (2018) Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits. *Aging Cell* 17:e12775. <https://doi.org/10.1111/acel.12775>
 267. Violet M, Delattre L, Tardivel M, Sultan A, Chauderlier A, Cailhiez R et al (2014) A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. *Front Cell Neurosci* 8:84. <https://doi.org/10.3389/fncel.2014.00084>
 268. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S et al (2010) Tau reduction prevents Abeta-induced defects in axonal transport. *Science* 330:198. <https://doi.org/10.1126/science.1194653>
 269. Wade-Martins R (2012) The MAPT locus—a genetic paradigm in disease susceptibility. *Nat Rev Neurol* 8:477–478. <https://doi.org/10.1038/nrneuro.2012.169>
 270. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 416:535–539. <https://doi.org/10.1038/416535a>
 271. Walter S, Jumpertz T, Hüttenrauch M, Ogorek I, Gerber H, Storck SE et al (2019) The metalloprotease ADAMTS4 generates N-truncated A β 4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. *Acta Neuropathol (Berl)* 137:239–257. <https://doi.org/10.1007/s00401-018-1929-5>
 272. Wang H, Megill A, Wong PC, Kirkwood A, Lee H-K (2014) Postsynaptic target specific synaptic dysfunctions in the CA3 Area of BACE1 knockout mice. *PLoS ONE* 9:e92279. <https://doi.org/10.1371/journal.pone.0092279>
 273. Wang H, Song L, Laird F, Wong PC, Lee H-K (2008) BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to ca3 synapses in the hippocampus. *J Neurosci* 28:8677–8681. <https://doi.org/10.1523/JNEUROSCI.2440-08.2008>
 274. Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R (2010) Amyloid beta from axons and dendrites reduces local spine number and plasticity. *Nat Neurosci* 13:190–196. <https://doi.org/10.1038/nn.2476>
 275. Wei Y, Qu M-H, Wang X-S, Chen L, Wang D-L, Liu Y et al (2008) Binding to the minor groove of the double-strand, tau protein prevents DNA from damage by peroxidation. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0002600>
 276. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. *Proc Natl Acad Sci USA* 72:1858–1862
 277. Weinger JG, Davies P, Acker CM, Brosnan CF, Tsiperson V, Bayewitz A et al (2012) Mice devoid of Tau have increased susceptibility to neuronal damage in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. *J Neuropathol Exp Neurol* 71:422–433. <https://doi.org/10.1097/NEN.0b013e3182540d2e>
 278. Whitson JS, Selkoe DJ, Cotman CW (1989) Amyloid beta protein enhances the survival of hippocampal neurons in vitro. *Science* 243:1488–1490. <https://doi.org/10.1126/science.2928783>
 279. Wijesekara N, Gonçalves RA, Ahrens R, De Felice FG, Fraser PE (2018) Tau ablation in mice leads to pancreatic β cell dysfunction and glucose intolerance. *FASEB J* 32:3166–3173. <https://doi.org/10.1096/fj.201701352>
 280. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A et al (2006) Control of peripheral nerve myelination by the β -secretase BACE1. *Science* 314:664–666. <https://doi.org/10.1126/science.1132341>

281. Wu Y-H, Swaab DF (2007) Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. *Sleep Med* 8:623–636. <https://doi.org/10.1016/j.sleep.2006.11.010>
282. Wu Z, Wang Z-H, Liu X, Zhang Z, Gu X, Yu SP et al (2020) Traumatic brain injury triggers APP and Tau cleavage by delta-secretase, mediating Alzheimer's disease pathology. *Prog Neurobiol* 185:101730. <https://doi.org/10.1016/j.pneurobio.2019.101730>
283. Xu F, Schillinger JA, Sternberg MR, Johnson RE, Lee FK, Nahmias AJ et al (2002) Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988–1994. *J Infect Dis* 185:1019–1024. <https://doi.org/10.1086/340041>
284. Yaghoobi H, Azizi H, Banitalebi-Dehkordi M, Mohammad Rezaei F, Arsang-Jnag S, Taheri M et al (2019) Beta-secretase 1 (BACE1) is down-regulated in invasive ductal carcinoma of breast. *Rep Biochem Mol Biol* 8:200–207
285. Yi S, Liu Q, Wang X, Qian T, Wang H, Zha G et al (2019) Tau modulates Schwann cell proliferation, migration and differentiation following peripheral nerve injury. *J Cell Sci*. <https://doi.org/10.1242/jcs.222059>
286. Yiannopoulou KG, Papageorgiou SG (2020) Current and future treatments in Alzheimer disease: an update. *J Cent Nerv Syst Dis*. <https://doi.org/10.1177/1179573520907397>
287. Yu W, Qiang L, Solowska JM, Karabay A, Korulu S, Baas PW (2008) The microtubule-severing proteins spastin and katanin participate differently in the formation of axonal branches. *Mol Biol Cell* 19:1485–1498. <https://doi.org/10.1091/mbc.e07-09-0878>
288. Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA (2008) Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. *J Neurosci* 28:1682–1687. <https://doi.org/10.1523/JNEUROSCI.5242-07.2008>
289. Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E et al (2013) Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTL6 and spastin. *Embo J* 32:2920–2937. <https://doi.org/10.1038/emboj.2013.207>
290. Zhang M, Zhang J, Zhang W, Yao Z (2018) Demyelination takes place prior to neuronal damage following intracerebroventricular injection of amyloid beta oligomer. *Neuropsychiatry* 8:1770–1785. <https://doi.org/10.4172/Neuropsychiatry.1000519>
291. Zhang Y, Walter R, Ng P, Luong PN, Dutt S, Heuer H et al (2016) Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: a longitudinal diffusion tensor imaging study. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0157218>
292. Zhao G, Cui M-Z, Mao G, Dong Y, Tan J, Sun L et al (2005) gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. *J Biol Chem* 280:37689–37697. <https://doi.org/10.1074/jbc.M507993200>
293. Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ et al (2017) Tau association with synaptic vesicles causes presynaptic dysfunction. *Nat Commun* 8:15295. <https://doi.org/10.1038/ncomms15295>
294. Zhukareva V, Sundarraj S, Mann D, Sjogren M, Blenow K, Clark CM et al (2003) Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. *Acta Neuropathol (Berl)* 105:469–476. <https://doi.org/10.1007/s00401-002-0668-8>
295. Zou C, Montagna E, Shi Y, Peters F, Blazquez-Llorca L, Shi S et al (2015) Intraneuronal APP and extracellular A β independently cause dendritic spine pathology in transgenic mouse models of Alzheimer's disease. *Acta Neuropathol (Berl)* 129:909–920. <https://doi.org/10.1007/s00401-015-1421-4>
296. Tissue expression of MAPT-Summary-The Human Protein Atlas. <https://www.proteinatlas.org/ENSG00000186868-MAPT/tissue>. Accessed 23 Jun 2020.
297. Tissue expression of APP-Summary-The Human Protein Atlas. <https://www.proteinatlas.org/ENSG00000142192-APP/tissue>. Accessed 23 Jun 2020.
298. Tissue expression of BACE1-Summary-The Human Protein Atlas. <https://www.proteinatlas.org/ENSG00000186318-BACE1/tissue>. Accessed 23 Jun 2020.
299. Tissue expression of PSEN1-Summary-The Human Protein Atlas. <https://www.proteinatlas.org/ENSG00000080815-PSEN1/tissue>. Accessed 23 Jun 2020.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.